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Abstract
Glioblastoma multiforme (GBM) is a destructive brain cancer that results in death 12 to
15 months after diagnosis. The purpose of this retrospective study was to determine if
variations in tumor size at diagnosis, treatment options, and survival rate occur in GBM
patients living in urban and rural areas of the United States. Using the behavior model of
health services as the theoretical framework, this study used secondary data sets of GBM
cases reported from 1988 to 2011 from the Surveillance, Epidemiology, and End Results
program. Tumor size was measured in millimeters; treatment was evaluated by
ascertaining the number of GBM patients who had surgical resection of their tumors,
radiation, and chemotherapy; and survival rate was evaluated using Cox Regression
analysis. With a sample size of 33,202 cases, data were examined using descriptive and
multivariable analyses with SPSS. Results showed statistically significant differences in
tumor size at diagnosis in rural patients compared to urban patients (p = 0.0085; p =
0.018), more urban patients were treated with radiation compared to rural patients (p <
0.001), and rural patients had poorer survival rates than urban patients (p < 0.001).
Finally, when controlling for region, race, age, gender, education, and income, longer
survival time was associated with urban status, female cases, and higher family income (p
< 0.0001), and greater age was associated with reduced survival time (p < 0.0001). Study
results could promote positive social change by identifying predictive variables
associated with health outcomes of GBM patients. It may also educate providers on the
risk of rurality of patients diagnosed with GBM, and inform lawmakers responsible for
the creation of healthcare policy and the equitable allocation of healthcare resources.
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Chapter 1: Introduction to the Study
Glioblastoma multiforme (GBM) is a malignant brain neoplasm known for its
destructive ability to invade healthy brain tissue at an accelerated rate, resulting in death
12 to 15 months after diagnosis (Holland, 2000). For this reason, Holland (2000) has
referred to GBM as “the terminator” (p. 6242). Once diagnosed, patients typically
undergo surgery for tumor removal followed by radiation and chemotherapy (Jelsma &
Bucy, 1967). Despite these treatment modalities, there are few long term GBM
survivors. Research has focused on finding effective and novel therapies aimed at
prolonging life such as immunotherapy, gene therapy, and viral therapy (Holland, 2000).
Immunotherapy research has focused on whether or not the body’s immune system
responds to the presence of a GBM tumor, referred to as a glioblastoma-specific immune
response (Haque, Nagarkatti, Nagarkatti, Banik, & Ray, 2010). Gene therapy research
has focused on switching out the defective portion of a gene causing GBM for a
functional portion of the gene (Kwiatkowska, Nandhu, Behera, Chiocca, & Viapiano,
2013). Moreover, viral therapy research involves the creation of a killer virus that
destroys cancer cells (Holland, 2000; Shah & Markert, 2004).
Despite the abundant research from a multitude of perspectives, no one really
knows what causes GBM. Research has identified three specific risk factors for brain
tumors in general: exposure to ionizing radiation, rare genetic mutations, and family
history (Bondy & Ligon, 1996; DeAngelis, 2001; Fisher, Schwartzbaum, Wrensch, &
Wiemels, 2007; Inskip, Linet, & Heineman, 1995). Unfortunately, only a very small
proportion of brain malignancies are attributable to these risk factors (Fisher et al., 2007).
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Other potential risk factors like cell phone use, smoking, and environmental exposures
have been explored in the development of brain neoplasms. However, these studies were
not definitive (Bondy et al., 2008; Connelly & Malkin, 2007; Gomes, Al Zayadi, &
Guzman, 2011). What is known is that in the United States, cancer incidence varies
from state to state (Centers for Disease Control and Prevention, 2013). In 2011, the ageadjusted brain and spinal tumor incidence for the United States was 6.4 per 100,000
people (all races), and state incidences ranged from 3.4 to 10.3 (Howlader et al., 2014).
In 2011, the age-adjusted incidence for GBM was 4.3 per 100,000 people (Howlader et
al., 2014). In this introductory chapter, I present a comprehensive overview for this
study; that is, an examination of the urban/rural variations of a specific brain tumor
known as GBM. The following topics specific to this study will be covered: background,
problem statement, purpose, theoretical foundation, major assumptions, scope and
delimitations, limitations, and significance.
Background of the Study
Cancer is a significant health issue worldwide. In 2012, over 14 million people
worldwide were diagnosed with cancer with a projected increase to 24 million by 2035
(Ferlay et al., 2013). An interesting pattern of brain cancer and various nervous system
cancers have emerged in the United States: higher rates in the southeast, northwest, and
midwest, and lower rates in the Rocky Mountains, northeast, and southwest (Devesa et
al., 1999).
One of the most pressing issues facing the field of public health is trying to
ascertain what makes some people healthy while other people are unhealthy. When

3
attempting to determine the factors that influence the health of people, the traditional
perspectives are categorized as follows: biological, environmental, lifestyle,
psychosocial, and access to health-related services (Turnock, 2009). The combination of
these factors is known as the determinants of health, and the interrelationships of these
factors contribute to the health or lack of health for individual and populations (Turnock,
2009; United States Department of Health and Human Services, 2014). Access to health
services and the quality of those health services influence health. In the 1980s, a great
deal of research examined access to healthcare resources from an urban versus rural
perspective. Studies showed that rural areas had fewer providers and hospitals than urban
areas (Reschovsky and Staiti, 2005; Ricketts, 2000). Consequently, rural populations had
less access to healthcare, used less healthcare resources, and paid more for healthcare
(Hartley, 2004). Newer urban/rural research has focused on the health of populations
from an environmental perspective, and the resultant effect on health behaviors (Arcury
et al., 2005; Goodman, Fisher, Stukel, & Chang, 1997; Higginbotham, Moulder, &
Currier, 2001). In this study, I will examine variables that affect health and potentially
identify factors that may contribute to different health outcomes for urban and rural
residents. Urban and rural environments will be thoroughly discussed in Chapter 2.
A tumor or neoplasm is defined as an abnormal tissue mass that can be either
benign or malignant (National Cancer Institute, n.d.). More specifically, a neoplasm of
the brain is defined as a mass of abnormal cells growing in the brain, and a malignant
brain tumor is one that is considered cancerous because the growth of abnormal cells are
out of control and destructive to healthy brain tissue (National Cancer Institute, n.d.).
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While most malignant tumors metastasize or spread to other body parts, malignant brain
tumors are not metastatic. Rather, malignant brain tumors infiltrate healthy brain tissue
and cause massive destruction (National Cancer Institute, 2009).
The most common malignant brain tumor in adults is known as a GBM (National
Cancer Institute, 2009, 2012). Patients with GBM may experience any of the following
conditions: persistent headaches, visual disturbances, mood and/or personality changes,
seizures, changes in ability to think, loss of appetite, vomiting, and/or difficulty with the
spoken word (Brandes et al., 2008; Davis & Stoiber, 2011; Fox, Lyon, & Farace, 2007;
Nolan & Gavrilovic, 2010). Patients who complain of the aforementioned symptoms will
usually undergo specific radiologic procedures known as computed tomography (CT)
and/or magnetic resonance imaging (MRI; Fink & Fink, 2013). CT and MRI scans can
only ascertain that a brain tumor exists. The way to determine the type of brain tumor is
through biopsy or tumor removal (Davis & Stoiber, 2011). The prognosis is quite poor
for patients diagnosed with GBM; that is, once diagnosed, median survival is 12 to 15
months from diagnosis (Deorah, Lynch, Sibenaller, & Ryken, 2006).
In any given cancer diagnosis, the size of the tumor is a significant prognostic
indicator of survival; that is, a smaller tumor size is a better prognosis for survival than a
larger tumor. In the case of GBM, patient symptomatology is usually related to a larger
tumor size found at diagnosis. It is not uncommon for GBM patients to be asymptomatic
until the tumor reaches an enormous size (Iacob & Dinca, 2009).
Another prognostic indicator of survival is the type and extent of treatment
options offered to patients diagnosed with GBM. Since the GBM tumor is aggressively
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fast-growing, highly vascular, and invasive in nature, treatment by necessity usually
includes surgery followed by adjuvant therapies of radiation and chemotherapy
(Hentschel & Lang, 2005). Surgery is usually the initial intervention in treatment of
GBMs, and the question most often raised is the degree of surgical aggressiveness
(Hentschel & Lang, 2003). The overall goals of surgical resection are three-fold:
diagnostic confirmation of GBM, symptom management, and improving overall survival.
According to Hentschel and Lang (2003), diagnostic confirmation relies on obtaining
adequately sized tissue samples for accurate histological diagnosis. Symptom
management involves a thorough understanding of the neurological symptoms caused by
GBMs. Hentschel and Lang noted that GBM tumors affect patients in two separate and
distinct ways: diffuse neurological symptoms or focal neurological deficits. Diffuse
neurological symptoms result from increased intracranial pressure that is due to the size
of the tumor and the edema (swelling) that it produces (Ammirati, Vick, Liao, Ciric, &
Mikhael, 1987; Fadul et al., 1988; Lacroix et al., 2001; Prabhu, 2007; Sawaya et al.,
1998). Symptoms of increased intracranial pressure are headache, nausea, vomiting,
blurred vision, alteration in the level of consciousness, and/or seizures. Examples of
focal neurological deficits would be a gradual decline in memory, judgment, language
problems, personality changes, and mobility and sensory changes (Ammirati et al., 1987;
Fadul et al., 1988; Prabhu, 2007; Sawaya et al., 1998). In most other areas of oncologic
tumors, the goal of surgery is complete tumor removal along with removal of large areas
of normal tissue surrounding the tumor (Hentschel & Lang, 2003). However, the
invasive nature of GBMs prevents the neurosurgeon from being able to completely
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remove the entire tumor as well as normal brain tissue (Hentschel & Lang, 2003;
Sahebjam, McNamara, & Mason, 2012). Surgical resection helps to reduce the diffuse
neurological symptoms caused by GBMs. In contrast, surgical resection may or may not
improve focal neurological symptoms. According to Stummer, van den Bent, and
Westphal (2011), the extensiveness of tumor removal is considered one of the strongest
prognostic factors in prolonging survival, decreasing tumor size, and managing
symptoms in GBM patients.
The hypothesis of this particular study is that rural GBM patients will have larger
tumors, experience fewer surgical resections, undergo fewer adjuvant therapies of
radiation and chemotherapy, and have decreased survival when compared to their urban
counterparts. This hypothesis is based on the following assumptions: rural populations
have limited access to health services, travel greater distances to access health services,
are in poor health, and have limited financial means.
Problem Statement
The impact of cancer on the United States population is multifaceted. According
to Gosschalk and Carozza (2003), studies have demonstrated variations in incidence,
mortality, and staging of particular cancers when examining the variables of race,
geographic areas of the United States, gender, and age. GBM is an aggressive brain
cancer with an abysmal mortality of 12 to 15 months once diagnosed (Ng, Kesari, Carter,
& Chen, 2011; Wen & Kesari, 2008). By the time GBM patients are diagnosed, their
tumor size is quite large, and the treatment options of surgery, radiation, and
chemotherapy are used to lengthen survival time beyond a year.
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Past GBM research has focused on environmental and occupational exposures
with ambiguous results (Connelly & Malkin, 2007; Gomes et al., 2011). Populationbased studies have examined the incidence of brain tumors and survival rates from a
gender perspective (Ohgaki et al., 2004; Ohgaki & Kleihues, 2005). However, there are
no studies that have examined the occurrence and survivability of GBM tumors from the
geographic perspective of living in rural versus urban regions. Consequently, the nature
of the relationship between living in urban versus rural regions and GBM is unclear.
Given the high mortality rates of GBM patients, if there is an association linking place of
residence and survival rates of GBM patients, then reduction of the barriers and
disparities that contribute to these negative outcomes might be achieved.
Significance
Anyone can develop cancer. Despite modern technology and cutting-edge
research to reduce cancer incidence and mortality, cancer prevalence is on the rise due to
an aging population (American Cancer Society, 2012; Gosschalk & Carozza, 2003). The
literature review in Chapter 2 provides significant and noteworthy information. For
example, the relationship between urban and rural populations and early cancer detection
is uncertain (Blair et al., 2006). Additionally, patients diagnosed with GBM have
unusually high mortality rates coupled with low survival rates owing, in part, to delays in
diagnosis and treatment (Mathiesen, Paredo, & Lönn, 2011). Furthermore, the GBM
tumor itself is characterized by aggressive growth and extensive infiltrative and invasive
vasculature. While some studies have examined the association of increased incidence of
certain cancers in rural populations (Gosschalk & Carozza, 2003; Singh, Williams,
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Siahpush, & Mulhollen, 2011), there are no studies that have investigated whether
rurality is a prognostic indicator for patients diagnosed with GBM.
Purpose of the Study
The purpose of this retrospective, quantitative study is to ascertain whether there
are variations in tumor size, treatment options, including surgical resection and adjuvant
therapies of radiation and chemotherapy, and survival rates between rural and urban
residents diagnosed with GBM. This study will use secondary data obtained from the
Surveillance and Epidemiology End Results (SEER) database. Rural and urban residents
are defined as men and women who are 20 years of age and older. Urban and rural areas
will be based exclusively on the SEER definition of using rural-urban continuum codes
(RUCCs) to distinguish urban from rural regions. This classification system
differentiates urban counties by population size. Alternatively, rural counties are
differentiated by the degree of growth, development, expansion, and proximity to an
urban county. This study will use the SEER database to ascertain if variations in tumor
size, treatment options, and survival rates exist among urban and rural area GBM patients
living in the United States.
Nature of the Study
The focus of this cohort study is on newly diagnosed GBM adult patients 20 years
of age and older. Participants will be drawn from the SEER database from 1988 through
2011. From a quantitative perspective, tumor size will be measured in centimeters as
reported in the SEER database. Patients with GBM tumors undergo surgery followed by
radiation therapy and chemotherapy (Hentschel & Lang, 2003). Surgery is the first
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course of treatment, and there is a great deal of controversy in the neurosurgical
community concerning the degree of surgical resection; that is, biopsy versus surgical
resection (Hentschel & Lang, 2005; Koul, Dubey, Torri, Kakumanu, & Goyal, 2012).
Some neurosurgeons initially prefer to perform a biopsy while other neurosurgeons
advocate for aggressive surgical resection. Over the last 2 decades, studies have
demonstrated the value of aggressive resection of GBMs by affecting overall survival
(Ammirati et al., 1987; Hentschel & Lang, 2003; Keles, Anderson, & Berger, 1999;
Lacroix et al., 2001; Sawaya et al., 2001). It is customary to follow aggressive surgical
resection with adjuvant therapies of radiation treatment and chemotherapy.
Groundbreaking research has shown definitively that surgery followed by radiation
therapy and chemotherapy has increased survival from a little more than 3 months to 7 to
12 months (Stupp et al., 2005). Finally, survival rates, otherwise known as survival
statistics, show the proportion of patients who survive cancer for a specified amount of
time. This study will use a common cancer statistic known as the 5-year survival rate
(Centers for Disease Control, 2014), or the proportion of patients who remain alive 5
years from initial diagnosis (Mayo Clinic, 2013).
Differentiating rural from urban areas is critical to this study. As a way of
discerning an urban region from a rural region, the United States Department of
Agriculture (2013) developed a classification system comprised of nine codes
corresponding to population size and adjacency to a metropolitan area. Every county in
the United States is consigned to one of the nine codes referred to as RUCCs. The SEER
database uses the RUCC system.
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Research Questions and Hypotheses
The following research questions and hypotheses form the basis for this
quantitative study:
Research Question 1: When comparing urban and rural patients with GBM, is
there a significant difference in GBM tumor size at diagnosis?
H01: When comparing urban and rural patients with GBM, there is no significant
difference in GBM tumor size.
H11: When comparing urban and rural patients with GBM, there is a significant
difference in GBM tumor size.
Research Question 2: When comparing urban and rural patients with GBM, is
there a significant difference in the number of patients who experienced surgical
resections?
H02: When comparing urban and rural patients with GBM, there is no significant
difference in the number of patients who experienced surgical resections.
H12: When comparing urban and rural patients with GBM, there is a significant
difference in the number of patients who experienced surgical resections.
Research Question 3: When comparing urban and rural patients with GBM, is
there a significant difference in the number of patients who experienced the adjuvant
therapies of radiation treatment and chemotherapy?
H03: When comparing urban and rural patients with GBM, there is no significant
difference in the number of patients who experienced the adjuvant therapies of radiation
treatment and chemotherapy.
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H13: When comparing urban and rural patients with GBM, there is a significant
difference in the number of patients who experienced the adjuvant therapies of radiation
treatment and chemotherapy.
Research Question 4: When comparing urban and rural patients with GBM, is
there a significant difference in survival rates?
H04: When comparing urban and rural patients with GBM, there is no significant
difference with survival rates.
H14: When comparing urban and rural patients with GBM, there is a significant
difference in survival rates.
Research Question 5: In the study population of GBM patients, is there a
significant difference in survival rates when controlling for region, race, age, sex,
educational level, and median family income?
H05: In the study population of GBM patients, when controlling for region, race,
age, sex, educational level, and median family income, there is no significant difference
in survival rates.
H15: In the study population of GBM patients, when controlling for region, race,
age, sex, educational level, and median family income, there is a significant difference in
survival rates.
The sample was drawn from the SEER database and consisted of subjects
diagnosed with GBM with the following attributes: (a) adult males and females, 20 years
of age and older, (b) urban or rural place of residence, (c) age at diagnosis, (d) year of
diagnosis between 1988 and 2011, (e) tumor size, (f) race/ethnicity: all races/ethnicities
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reported, (g) surgical resection, (h) adjuvant therapies: radiation therapy and
chemotherapy, and (i) survival time: 5 years after diagnosis. The data were analyzed
using the latest version of SPSS. For the purpose of this study, the independent variable
was region, apportioned to urban and rural regions using RUCCs. The level of
measurement of the independent variable was nominal. There were four dependent
variables: tumor size at initial diagnosis, surgical resection, adjuvant therapies of
radiation treatment and chemotherapy, and survival rate. The level of measurement for
tumor size was ordinal; that is, tumor size was measured in centimeters. Ordinal
measurements assign observations into categories that can be put into rank order and do
not quantify differences (Gerstman, 2008, p. 5). Since rank orders do not quantify
differences, conditions of normality and equal variance are absent. Thus, a
nonparametric statistic was used. Data analysis for the first research question used the
independent samples t test. For the second (surgical resection) and third research
questions (adjuvant therapies of radiation treatment and chemotherapy), the level of
measurement was nominal. GBM patients were identified as to whether or not they
experienced surgical resections (yes/no), radiation treatment (yes/no), and chemotherapy
(yes/no). Data analysis for surgical resections, radiation treatment, and chemotherapy
used the independent samples t test. The fourth research question involving survival rate
used a combination of Kaplan-Meier for univariate analysis and Cox proportional hazards
(regression analysis) for multivariate analysis of survival differences between groups
(metropolitan and nonmetropolitan). Finally, the fifth research question used multiple
regression modeling to determine the best predictive model based on the independent
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variables of region, age, marital status, race, educational level, and family income in the
study population of GBM cases (Klein, 2010; Klein, Ji, Rea, & Stoodt, 2011).
Theoretical Base
The theoretical framework used for this study was Andersen’s behavior model of
health services use developed in the late 1960s (Andersen, 1995). With a major focus on
accessing health care, this model has undergone several iterations over the last 40 years.
The original focus was on the family unit while the later models explored the individual.
Regardless of the focus, the model sought to understand how and why health services
were used as well as any factors that contributed to or hindered one’s access to medical
care. Andersen (1995) postulated that there were three essential factors that affected
one’s use of health care services or access to medical care: predisposing factors, enabling
factors, and need factors. Predisposing factors are defined as demographic features of
human beings like age, gender, ethnicity, education level, occupational background, and
ethnicity, and basic health beliefs (Andersen, 1995). Enabling factors are viewed as
resources that contribute to one’s use of health services like income, insurance coverage,
and the geographic region where one lives (Andersen, 1995). Finally, need factors are
defined as the most immediate reasons why an individual would seek health care like
illness or trauma (Andersen, 1995). Placing this study within the context of the
theoretical foundation, it is possible that because of the predisposing characteristics and
enabling resources specific to rural patients, delays in accessing health care resources
might lead to larger tumor size, decreasing KPS, and poorer survival rates of rural GBM
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patients. This model will be further explored in Chapter 2. Figure 1 shows the health
behavior model by Andersen.

Figure 1. The health behavior model as put forth by Andersen. Andersen, R.M. (1995).
Revisiting the behavioral model and access to medical care: Does it matter? Journal of
Health and Social Behavior, 36(1), 1-10. Reprinted with permission (Appendix B).
For this study, the following constructs of the health behavior model form the
basis of data collected from the SEER database:
•

Health Care System: Location, that is, rural versus urban areas using the
RUCCs used by the SEER database.

•

Predisposing characteristics: Demographic factors such as age, gender,
and race obtained through the SEER database. Educational level or
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median family income is not available from the SEER database but is
available at the county level. For this study, educational level and median
family income were obtained from county data.
•

Enabling resources: Financial resources, insurance coverage, rurality, or
the degree of urban versus rural locations (distance from healthcare
resources, access to transportation as defined by RUCC in the SEER
database).

•

Need: The reason that causes the individual to seek healthcare services
(diagnosis of GBM) and measured by tumor size, treatment options, and
survival rates from the SEER database. Please see Table 1.

Table 1
HBM Constructs and Relationship to Study Variables
HBM construct
Description
Health care system Location
Predisposing
characteristics

Demographic data

Enabling resources

*Financial data
*Insurance
*Rurality
Diagnosis of GBM

Need

Database
SEER: RUCC Codes (urban or
rural)
*SEER: Age-Sex-Race
*County Data: Educational
level and median family
income
*SEER: RUCC Codes
*County Data: median family
income and insurance
SEER: tumor size-treatment
options-survival ratemortality rate

Study variable
Independent
Dependent

Independent
Dependent
Dependent
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Definition of Terms
Glioblastoma Multiforme (GBM): A malignant brain tumor known as a Grade-4
glioma.
Glioma: A broad term that describes a tumor that originates from glial cells
specific to the brain. Glial cells provide support and protection to the nervous system.
Rural-urban classification code: The SEER database uses the geographical
region known as a county to define urban and rural regions. An urban county is defined
by population size. Alternatively, a rural county is defined by how close it is to an urban
area. See Table 2 below.
Table 2
Urban and Rural Continuum Codes
Metropolitan counties
Code
1
2
3
Nonmetropolitan
Counties
Code
4
5
6
7
8
9

Definition
Metro area with 1 million or more people
Metro area with 250,000 to 1 million people
Metro area with fewer than 250,000 people

Adjacent to metro area, 20,000 or more people
Nonadjacent to metro area, 20,000 or more people
Adjacent to metro area, 2,500 to 19,999 people
Nonadjacent to metro area, 2,500 to 19,999 people
Adjacent to metro area, < 2,500 people or totally rural
Non adjacent to metro area, < 2,500 or totally rural

Note. United States Department of Agriculture (2013). Rural-urban continuum codes. Retrieved
from http://www.ers.usda.gov/data-products/rural-urban-continuum-codes/documentation.aspx.
Table is in the public domain. Permission to reproduce was not required.

Survival rate: Survival rate is a term used when examining survival analysis,
indicative of a certain percentage of people in a study who are alive for a given period of
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time after diagnosis (National Cancer Institute, n.d.). This study will express survival
rate as the percent of adults diagnosed with GBM still alive after 5 years.
Tumor size: For the purpose of this study, a classification system developed by
SEER will be used to determine GBM tumor size. This system, known as the Extent of
Disease, uses a 3-digit numerical code to describe tumor size (National Institute of
Health, 2007). Using the largest diameter of the tumor, the size of the tumor is coded
(NCI, 1998). These data are used by health care providers to determine the extent of a
patient’s disease and prognosis of the particular cancer involved. It is often referred to as
collaborative staging. Every type of neoplasm has its own collaborative stage for tumor
size. Table 3 is specific to brain tumors.
Table 3
Brain: Collaborative Stage for Tumor Size
Code
000
001-988
989
990
991
992
993
994
995
999

Description
No mass or tumor found
001 – 988 millimeters (mm). Exact size to nearest mm
989 mm or larger
Microscopic only and no size of given
Tumor is “less than 1 centimeter (cm)”
Tumor is “less than 2 cm” or “greater than 1 cm” or “between 1 cm and 2 cm”
Tumor is “less than 3 cm” or “greater than 2 cm” or “between 2 cm and 3 cm”
Tumor is “less than 4 cm” or “greater than 3 cm” or “between 3 cm and 4 cm”
Tumor is “less than 5 cm” or “greater than 4 cm” or “between 4 cm and 5 cm”
Size not known due to lack of documentation

Note. Adamo, M., Dickie, L., & Ruhl, J. (May 2014). 2014 SEER Program Coding and Staging Manual.
National Cancer Institute, Bethesda, MD: United States Department of Health and Human Services. Table
is in the public domain. Permission to reproduce was not required.
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Assumptions
In this study, I focused on differences in GBM tumor size at diagnosis, treatment
options, and survival rates in urban and rural GBM patients across SEER registries. The
following assumptions are important in understanding the context of this particular study.
First, the scope of this study is limited to an examination of urban and rural GBM
patients. Second, a GBM tumor is a Grade 4 neoplasm, and by the time symptoms
appear, it is considered to be in an advanced stage of development. Third, rural
populations differ from their urban counterparts. Fourth, there are specific features of the
rural environment that create obstacles to one’s ability to access healthcare like a lack of
health insurance or financial resources to pay for needed healthcare services, lack of
healthcare resources themselves, and/or the distance and travel time to healthcare
resources. Fifth, urban regions have a greater concentration of physicians, hospitals,
specialty healthcare centers, and advanced diagnostic capabilities than rural regions.
Scope and Delimitations
Since this study is descriptive in nature only, one cannot draw conclusions of
causation. Furthermore, this study focuses only on the subpopulation of adult patients
diagnosed with GBM. Consequently, there is an inherent sample bias that undermines
the study’s external validity.
Limitations
First and foremost, this study is based exclusively on secondary data obtained
from the SEER database representing 28% of the United States population (National
Cancer Institute, n.d.). This limits the generalizability of results to all populations. To
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minimize this limitation, descriptive statistics will be used to describe study results, and
confounding variables will be controlled. Second, confounding conditions of the study
population pose a threat to internal validity (Graves, 2011). Since GBMs are most
common in the elderly who have complex health issues, survival could be affected by
potential confounding conditions other than the GBM itself. The SEER database reports
only on cancer information and incidence. It does not address lifestyle factors or causes
of cancer. Since this is a quantitative, retrospective cohort study, the use of descriptive
statistics should minimize this particular limitation. Third, since the database will cover a
23-year timeframe from 1988 to 2011, the loss of patients to follow-up could result in
either an overestimate or underestimate of study results. Loss of patients from SEER
registries are primarily due to patient interest, name and address changes, and/or death.
With the GBM population, survival is usually 12 to 15 months or less from time of
diagnosis. Since SEER does follow all patients until death, and the survival rate for
GBM patients is poor, the likelihood of losing patients to follow-up should be minimal.
Fourth, this particular study is based exclusively on the SEER definitions of RUCCS,
which ultimately affect the generalizability of results. There is no single, universally
accepted definition of rural. However, counties are the most commonly used geographic
component of rural definitions. The advantages of using “counties” to describe urban
from rural areas are that they are simple to understand and their boundaries are very
stable over time. Additionally, many national health data sets use counties as a core
geographic unit. Finally, RUCCs data are provided as a numeric continuum, and as such,
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must be treated as ordinal data since there is no equal distance between codes (Hall,
Kaufman, & Ricketts, 2007).
Significance of the Study
With the recent advances in genetics and genomes, a plethora of research has
focused on the identification of genes specific to GBM. In contrast, very little research
has been done to study brain cancer from a geographical perspective. This project is
unique in that examining patients diagnosed with GBM from an urban-rural perspective
has never been done before, highlighting a significant gap in the literature. Specifically, I
will examine the association between exposure to rural versus urban locations on tumor
size at diagnosis, the number of patients that experienced surgical resection, the number
of patients who experienced adjuvant therapies of radiation treatment and chemotherapy,
and survival of GBM patients. The independent variables are region, dichotomized to
urban or rural areas, race, age, sex, educational level, and family income. The dependent
variables are tumor size, surgical resection, adjuvant therapies of radiation treatment and
chemotherapy, and survival rates. GBMs are a significant public health issue.
Identification of the associations of these variables may provide insight into earlier
detection resulting in improved survival rates GBM patients. This study can significantly
impact social change by identifying geographical predictive variables associated with
health outcomes of GBM patients, thereby leading to earlier detection and improved
survival rates of individuals and populations.
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Summary and Transition
Cancer is a worldwide health issue. GBM is a malignant brain tumor in adults,
distinctively characterized by its aggressiveness to spread rapidly, invade deeply and
infiltrate healthy brain tissue, and result in death 12 to 15 months after initial diagnosis.
Delays in detection and treatment contribute to its dismal prognosis. In this study, I
examined the relationship between GBM patients and the geographic regions where they
live and work. I also explored the variables of tumor size, the treatment modality of
surgical resection, adjuvant therapies of radiation treatment and chemotherapy, and
survival of GBM patients in urban and rural regions. Using the SEER database covering
1988 through 2011, descriptive and multivariable analyses of data provided an
examination into the complex phenomena of GBM in rural and urban populations.
Analysis of this type can provide valuable information to those responsible for the
creation of healthcare policies and the allocation of healthcare resources.
Chapter 2 includes a review of the existing literature on GBM in adult
populations, the theoretical framework associated with this study, and a discussion of
healthcare access. Chapter 2 also includes a discussion of geographic variations of
healthcare in general, including rural and urban differences in GBM incidence and
survival, provides an overview of brain tumors and the epidemiology of GBM, and
identifies the gap in the literature with respect to geographic differences specific to the
GBM population. I conclude Chapter 2 with an explanation for ongoing GBM research.
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Chapter 2: Literature Review
In this chapter, I provide a systematic review of the literature pertinent to this
study. I first explore the theoretical framework used for this study. Additionally, I
discuss the geographic variations of GBM in the United States. I then explore the clinical
attributes of GBM including its definition, symptomatology, detection, prognostic
characteristics, diagnosis, and treatment options followed by the epidemiological
characteristics of GBM from a person, place, and time perspective based on the most
current literature. Major studies on GBM will be reviewed and summarized.
Specifically, this discussion compares and contrasts urban and rural regions of the United
States by examining tumor size at diagnosis, the number of patients that experienced
surgical resection, the number of patients who experienced the adjuvant therapies of
radiation treatment and chemotherapy, and survival rate. Finally, an analysis of this
literature review highlights a knowledge gap regarding urban and rural variations in
tumor size, the treatment modality of surgical resection, adjuvant therapies of radiation
treatment and chemotherapy, and survival rate in GBM patients.
The literature review included an evaluation of the following databases available
through the internet: the Academic Search Premier database of Walden University,
MEDLINE, PUBMED, Science Direct, and ProQuest for dissertations. This approach
generated hundreds of peer reviewed articles on GBM. Peer-reviewed journal articles
were included if they were published in English and without date limitations.
Publications referenced in peer-reviewed articles specific to GBM were also included in
the search strategy. Key terms used in the search strategy included glioblastoma
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multiforme, GBM, gliomas, and brain tumors combined with the following terms:
geography, geographic variation, regional, regional variation, urban-rural,
metropolitan-nonmetropolitan, brain tumors, primary brain tumors, gliomas, GBM
epidemiology, prognosis, and SEER.
Theoretical Framework
This study used Andersen’s behavioral model of health services use (1995) as its
theoretical framework. This theoretical framework has been used in studies that
examined access to healthcare, determined the quality of care delivered, and evaluated
associated outcomes (Blustein & Weitzman, 1995; Fryer et al., 1999; Love & Lindquist,
1995). The framework for this study is based on the hypothesis that late access to general
and cancer diagnostic services for patients experiencing GBM may potentially lead to
increased tumor size, decreased treatment options, and decreased survival rates.
Concerned with inequalities to medical care access, Andersen initiated studies on
the concepts of access in 1968. The behavioral model (Figure 2) focused on the family
unit, how and why the family used health services, and access to medical care.
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Figure 2. The initial behavioral model (1960s).Andersen, R.M. (1995). Revisiting the
behavioral model and access to medical care: Does it matter? Journal of Health and
Social Behavior, 36, 1-10. Reprinted with permission.
Andersen’s (1995) model infers that an individual’s use of healthcare relies on
one’s general predisposition concerning health services, issues that enable or block
utilization of services, and one’s inherent need to seek health care. Andersen and Aday
(1974) further examined concepts of medical care access and developed a more cohesive
theoretical framework showing initial measures of access to medical care (Figure 3).
Andersen (1995) noted that the purpose of the initial measures of access was to identify
situations that either enhance access to healthcare services or obstruct access to the same
services.
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Figure 3. Initial measures of access of the health behavior model. Andersen, R.M.
(1995). Revisiting the behavioral model and access to medical care: Does it matter?
Journal of Social Behavior, 36, 1-10. Reprinted with permission.
By 1995, Andersen revised the original focus on access to a behavioral approach
of health services use with the assertion that using health services should either maintain
the health status of the population served or improve the population’s health status, both
perceived by the population and/or evaluated by health professionals (Andersen,
Davidson, & Ganz, 1994; Figure 7). The model also recognizes the importance of how
the external environment contributes to the use of health services. Andersen (1995) noted
that this final model shows the many influences of health services use and eventually
health status. This model provides feedback loops indicated by the arrows in the diagram
that highlight the interrelatedness of all the factors that make up this model (Andersen,
1995).
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Figure 4. An emerging model identified as Phase 4 of the health behavior model.
Andersen, R.M. (1995). Revisiting the behavioral model and access to medical care:
Does it matter? Journal of Social Behavior, 36, 1-10. Reprinted with permission.
The following concepts, identified by Aday and Andersen (1974), are critical to
understanding the behavioral model:
1. Health policy: Viewed as a starting point for understanding access to health care.
Aday and Andersen (1974) acknowledged that those professionals involved with
health planning and creating policy are concerned with effecting health policy in
order to improve access to medical care.
2. Health care delivery system: Comprised of resources and organization.
a. Resources are defined as the workforce and funds devoted to health care
including health care personnel, physical structures where health care is

27
delivered, and equipment and supplies used to provide health care
services.
b. Organization refers to what and how the system handles its resources. The
components of organization are entry and structure.
i. Entry is the process of entering the healthcare system, otherwise
known as access.
ii. Structure refers to the characteristics of the system that determines
the needs of the patient at the time of service.
3. Characteristics of the population at risk: Viewed as the individual’s determinants
of health care utilization.
a. Predisposing factors are the sociocultural aspects of individuals that exist
like age, gender, educational level, occupation, race, and ethnicity
(Andersen, 1995).
b. Enabling factors involve resources that promote the use of health care
such as adequate income and insurance coverage (Andersen, 1995).
Additionally, the location of healthcare services is significant for people’s
ability to access health services (Aday & Andersen, 1974).
c. Need factors are the reasons why health care is sought (illness, accident)
(Andersen, 1995).
4. Utilization of health care services: Those characteristics that identify what
happens to the individual upon entry (or nonentry) into the system (Aday &
Andersen, 1974; Andersen, 1995).
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5. Consumer satisfaction: Measures users’ satisfaction with the quantity or quality of
care actually received. This dimension of access is measured by subjective
perceptions in relation to convenience, coordination, cost, courtesy, and
information provided.
Andersen’s (1995) model is most meaningful in considering access from the
perspective of whether those people who need care actually get into the system. A more
precise model for measuring or quantifying access will improve awareness of the
availability and utilization of health services by certain subgroups within the population.
Graves (2011) noted that understanding the specific needs, predisposing factors, and
enabling resources of people living in particular regions can ultimately effect alterations
in health outcomes. The assessment of tumor size, treatment options, and survival rates
for GBM patients and the relationship to location of health services (urban versus rural
areas) can potentially improve survival rates. Therefore, the adaptation of Andersen’s
HBM model to the GBM population in urban versus rural areas is presented in this study.
Healthcare Access
Aday and Andersen (1974) defined access as the ability to utilize healthcare
services whenever and wherever the need arises. Alternatively, potential access refers to
having the resources that promote the use of healthcare services, otherwise known as
enabling resources (Andersen, 1995; Graves, 2011). Therefore, if one possesses more
enabling resources, chances are that the healthcare system will be used. Alternatively, a
shortage or absence of enabling resources could ultimately result in one’s decreased
ability to enter the health care system. A 1973 report by the United States Department of
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Agriculture examined the provision of healthcare services in rural versus urban regions
and concluded that populations living in rural regions do not have equal access to
healthcare compared to their urban counterparts. The report goes on to say that rural
regions are deficient in medical personnel and healthcare facilities, and populations in
rural regions do not have the economic capabilities to afford the costs of illness (Lepine
& Le Nestour, 2012).
The concept of access describes the association or connection between the basic
need for healthcare and the actual delivery of healthcare. From a conceptual perspective,
access is further divided into the following categories: acceptability, accessibility,
accommodation, affordability, and availability. Accessibility is subdivided into socioorganizational and geographical aspects such as distance transportation and travel time to
and from health care services (Aday & Andersen, 1974). However, most measures of
access highlight the actual location of healthcare services and how the needs of the
associated population in question are being met (Graves, 2009).
In 1971, Hart described the state of heath care services in Great Britain as an
imbalance between need and provision. Hart observed that the lower social classes in
Great Britain had higher morbidity and mortality rates than those in higher social classes.
He proposed the Inverse Care Law where “the availability of quality medical care varies
inversely with the need for care in the particular population served” (Hart, 1971, p. 405).
Despite present-day advances in healthcare, the inverse relationship of need and
provision persists. According to Murray and Lopez (1997), this inverse relationship is
most evident in developing countries. Gatrell (2002) noted that in 1990, developing
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countries had 90% of the disease burden but only 10% of global health expenditures.
Current literature on developed countries has suggested that this inverse relationship
continues to exist in Britain’s healthcare system today (Lovett, Haynes, Sunnenberg, &
Gale, 2002).
Access and Health Outcomes
Aday and Andersen (1974) identified health outcomes as the end products of
access and include the indicators of health status, satisfaction, and quality of life. Past
research has demonstrated differences in health outcomes by specific subpopulations who
faced barriers to accessing high quality health care (Black, Langham, & Petticrew, 1995;
Blustein & Weitzman, 1995; Bullen, 1996; Goodman et al., 1997; Sempos, Cooper,
Kovar, & McMillen, 1988; Weitzman et al., 1997). Differences in health outcomes might
be how frequently a disease affects a group or how often the disease results in death.
These differences in health outcomes are known as healthcare disparities, and when
disparities are identified, it is assumed that inequalities in healthcare could exist (Agency
for Healthcare Research and Quality, 2013). Inequalities result in underserved, at-risk
populations like minority groups, the elderly, women, children, the elderly, low-income
populations, rural residents, and special needs populations (Agency for Healthcare
Research Quality, 2004).
Access and Rural Health
There are numerous definitions of rural regions or rurality that have been used by
various federal agencies of the United States. For this particular study, the definition
developed by the United States Department of Agriculture (USDA) will be examined.
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The Economic Research Service (ERS), a division within the USDA created a model
known as RUCCs to describe the distinctions between rural regions and urban regions
(USDA, 2002). The RUCCS model is based on metropolitan (urban) versus
nonmetropolitan (rural) regions of the United States. In Table 4, the model starts with
metro or urban regions classified into three separate categories by the size of the
population. Conversely, nonmetropolitan regions are classified by how close they are to
urban regions, often referred to as adjacency. In Table 4, Codes 1 through 3 refer to
urban counties by population size, while Codes 4 through 9 identify rural counties by
their proximity or adjacency to an urban area with a given population size (USDA, 2002).
Table 4
Urban and Rural Classifications
Metropolitan Counties
Code
1
2
3
Nonmetropolitan Counties
Code
4
5
6
7
8
9

Definition
Metro area with 1 million or more people
Metro area with 250,000 to 1 million people
Metro area with fewer than 250,000 people

Adjacent to metro area, 20,000 or more people
Nonadjacent to metro area, 20,000 or more people
Adjacent to metro area, 2,500 to 19,999 people
Nonadjacent to metro area, 2,500 to 19,999 people
Adjacent to metro area, < 2,500 people or totally rural
Non adjacent to metro area, < 2,500 or totally rural

Note. Economic Research Service (2013). 2013 rural-urban continuum codes. Retrieved
from http://www.ers.usda.gov/data-products/rural-urban-continuumcodes/documentation.aspx.Table is in the public domain. Permission to reproduce is not
required.
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Geographic Perspectives: Urban Versus Rural Regions
From a public health perspective, there has always been significant interest in the
health of populations from a geographic vantage point of where people reside. Research
has demonstrated the important connection between place of residence and health
(Eberhardt & Pamuk, 2004; Tunstall, Shaw, & Darling, 2004). Specifically, there is a
dearth of research on health care and health outcomes in rural and urban areas. This
research originally focused on access, cost, and the distribution of healthcare resources
like medical providers, clinics, and hospitals (Aday & Andersen, 1974; Hartley, 2004;
Vlahov, Galea, & Freudenberg, 2005). Current research in the rural-urban arena is on the
determinants of health and the resultant similarities and differences on health behaviors
and outcomes (Meade & Emch, 2010).
At least half of the world’s population lives in urban regions (United Nations
Population Fund, 2011). From a social and environmental perspective, urban life is quite
different from rural life. Urban life is distinguished by the following characteristics:
dense and diverse populations, complex systems, extensive social and political networks,
increased growth of slums, a dearth of hazardous waste sites, increased indoor and
outdoor pollution, noise exposure, and inadequate, over-crowded living conditions
(Lauber & Tidball, 2014; Vlahov et al., 2005).
Alternatively, rural regions show populations that are more spread out across
wider farmland type areas and characterized by a lower socioeconomic status, earlier
mortality before 75 years of age (Eberhardt & Pamuk, 2004), along with higher mortality
rates from accidents and suicide (Eberhardt et al., 2001). Rural populations tend to
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smoke excessively (Monroe, Ricketts, & Savitz, 1992), and have higher mortality rates
from chronic obstructive pulmonary disease (Eberhardt et al, 2001). Research has shown
mixed results for cancer mortality rates across rural regions of the United States. For
example, Yabroff et al. (2005) demonstrated higher mortality rates due to cervical cancer
in women living in the central California valley, southern portions of the United States,
and rural Appalachia, compared to their urban counterparts. A 2011 study examined the
mortality rates for all cancers in the United States, and found that rural residents had
higher cancer mortality of the prostate, cervix, lung, and colon (Singh et al., 2011).
Research has also demonstrated that populations living in rural regions travel longer
distances and to urban areas to obtain needed medical care (Chan, Hart, & Goodman,
2006). Ricketts (2000) specifically pointed out that rural areas are constantly suffering
from physician shortages since only 11% of all physicians practicing in the United States
are based in rural areas. Reschovsky and Staiti (2005) determined that the physician
shortage is far greater among specialists in rural areas. Since rural patients have a lower
socioeconomic status, they are less likely to have insurance which discourage them from
seeking needed medical care. When illness becomes so great and patients have to obtain
needed care, they have to wait longer for appointments due to physician shortage, have to
travel far greater distances to see specialists, and are usually in advanced stages of
disease progression.
Brain Tumors: General Overview
The brain and spinal cord, taken together are known as the Central Nervous
System (CNS; Buckner et al., 2007). The CNS regulates all the vital functions of the
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body such as all body movements, speech, and thoughts (Buckner et al., 2007). When a
brain tumor occurs in the CNS, it can significantly affect one’s thought processes,
communication abilities, and movement capabilities (American Society of Clinical
Oncology, 2012). Brain tumors occur when normal brain cells change and grow
uncontrollably ultimately forming a collection of abnormal cells (National Cancer
Institute, 2009). Brain tumors are classified as primary or secondary. Primary brain
tumors start in the brain, and rarely metastasize to other parts of the human body
(National Cancer Institute, 2009). Secondary brain tumors, otherwise known as
metastatic brain tumors, occur when cancer cells from another part of the body, such as
the lung, breast, or colon, spread or metastasize to the brain via the bloodstream (National
Cancer Institute, 2009). The distinction between primary and secondary brain tumors is
clinically important since treatment modalities are quite different.
There are over 100 different types of primary brain tumors that are identified and
categorized by microscopic examination otherwise known as histopathologic
classification. Approximately 50% of these brain tumors come from a specific cell in the
brain known as a glial cell (Jellinger, 1978). First identified by the German pathologist,
Rudolf Virchow, in 1860, these primary brain tumors are known as gliomas, and Virchow
used terms like teleangiectatic and hemorrhagic to further describe these tumors
(Jellinger, 1978). Gliomas originate from primitive cells known as astrocytes, and brain
tumors that originate from astrocytes are called astrocytomas (Jellinger, 1978).
Astrocytomas are given a grade from I to IV for how much the tumor looks like normal
brain tissue and how quickly the cells grow often referred to as aggressiveness (American

35
Society of Clinical Oncology, 2014). This grading system, specific to brain tumors, is
primarily used to determine a patient’s prognosis. Lower grades are less abnormal and
slow-growing while higher grades are more abnormal and fast-growing. The World
Health Organization (WHO) classifies astrocytomas in the following ways:
•

Grade I (Pilocytic Astrocytoma): A brain tumor that grows slowly, does not
metastasize to other areas of the CNS, the least malignant, and accounts for 2% of
all brain tumors (American Society of Clinical Oncology, 2014).

•

Grade II (Low-grade Astrocytoma): A relatively slow-growing brain tumor that
may or may not metastasize to other parts of the CNS, tends to recur posttreatment, and accounts for 3% of all brain tumors (American Society of Clinical
Oncology, 2014).

•

Grade III (Anaplastic Astrocytoma): A malignant brain tumor that grows quickly,
invades nearby brain tissue, and accounts for less than 5% of all brain tumors
(American Society of Clinical Oncology, 2014; Louis et al., 2007).

•

Grade IV (GBM): An extremely aggressive and highly malignant brain tumor
that rapidly invades normal brain tissue, characterized by areas of necrosis (dead
cells) in the center of the tumor when viewed under a microscope, and accounts
for 25% of all primary brain tumors (American Society of Clinical Oncology,
2014; Louis et al., 2007; Wang et al., 2011).
Glioblastoma Multiforme: Definition and Description
The term glioblastoma multiforme was first used in 1925 by Globus and Straus as

a replacement for the category known as spongioblastoma multiforme. On microscopic
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examination, a GBM is typically recognized as having large areas of necrosis and
microvascular proliferation (the formation of new blood vessels from preexisting blood
vessels), a hallmark sign in aggressive cancers (Shabason, Tofilon, & Camphausen,
2011). In general, GBM tumors have the appearance of malignant cells surrounding
areas of necrosis and hemorrhage (Louis, Holland, & Cairncross, 2001; Shabason et al.,
2011). Due to its hemorrhagic, proliferative, and aggressive qualities, the median
survival time for a newly diagnosed patient is approximately one year (Aldape, Okcu,
Bondy, & Wrensch, 2003).
Epidemiology of Glioblastoma Multiforme: Person, Place, and Time
In the United States, primary malignant brain tumors are rare, accounting for
approximately 2% of all adult cancers (American Cancer Society, 2012a; Patel et al.,
2014). Despite their rarity, brain cancer incidence has increased over the last 30 years
while survival rates remain abysmally poor (Deorah, Lynch, Sibenaller, & Ryken, 2006).
From 1973 to 2001, over 38,000 cases of malignant brain tumor were reported to the
SEER 9 database, and almost 17,000 cases were diagnosed as GBM (Deorah et al.,
2006). GBM is the most commonly-occurring brain neoplasm in adults. .The following
epidemiological facts are known about GBM:
•

1.6 times more common in men than women (Ivan, Tate, & Clarke, 2012).

•

Two to three times higher among Caucasians than blacks, American Indians and
Alaskan natives, and Asian-Pacific Islanders race groups (Ohgaki & Kleihues,
2005).
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•

Occurs more frequently in older adults (Dolecek, Propp, Stroup, & Kruchko,
2012), and increase with age with primary occurrence in adults from 45-70 years
old although the highest rates occur in the 75 to 84 year-old age group (Ivan, Tate,
& Clarke, 2012; National Cancer Institute, 2012).

•

In most elderly patients, GBMs arise abruptly and grow quickly, impairing
cognition and drastically reducing functional independence (Hutterer, 2009).
Furthermore, GBM treatments in older people are less effective and more toxic
than in younger people.

As in the United States, GBM is the most common primary brain tumor worldwide,
with an incidence of 2-3 new cases per 100,000 people per year (Central Brain Tumor
Registry of the United States, 2012). The relative survival estimates for patients
diagnosed with GBM show less than 5% of patients surviving five years post-diagnosis
(Central Brain Tumor Registry of the United States, 2012). Aldape et al. (2003) noted
that the median survival for patients newly diagnosed with GBM and undergoing typical
treatment options is 12 months. Despite the advent of modern-day diagnostic capabilities
along with improved and enhanced treatment modalities, survival time has not
significantly improved.
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Figure 5. Microscopic view of normal brain tissue and brain tissue with a GBM.
Note. College of American Pathologists (2012). Brain tumor: Glioblastoma.
http://www.cap.org/apps/docs/reference/myBiopsy/glioblastoma.html. Figure is in the
public domain. Permission to reproduce not required.

Figure 6. Magnetic resonance image (MRI) revealing a mass in the brain that was later
shown to be a glioblastoma multiforme (indicated by arrow).
Note. National Institutes of Health (2014). Glioblastoma multiforme. The Cancer
Genome Atlas. Retrieved from
http://cancergenome.nih.gov/cancersselected/glioblastomamultiforme. Figure is in the
public domain. Permission to reproduce not required.
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Treatment Modalities of GBM
The management of GBM has progressively evolved over the last two decades
with new technological advances that have led to improve diagnosis, site-specific
radiation techniques, surgical procedures, and improved chemotherapies. Yabroff,
Harlan, Zeruto, Abrams, and Mann (2012) note that GBM treatment is limited by its
primary location (brain) and its infiltrating vascularity. According to Ivan, Tate, and
Clarke (2012), prior to 2005, the typical standard of care for newly diagnosed GBM
patients was surgical removal of the tumor followed by radiation therapy (adjuvant
radiotherapy). Whether or not chemotherapy administration was beneficial in the
treatment of GBM was not clear (Yabroff et al., 2012). However, in 2005, a landmark
study demonstrated that overall survival was prolonged if the patient had maximal
surgical resection of the tumor followed by concomitant therapies of radiation and
administration of a chemotherapeutic agent identified as temozolomide (Stupp et al.,
2005).
Prognostic Factors of GBM
The neuro-oncologic community universally agrees that a diagnosis of GBM is
associated with a dismal prognosis (Stupp et al., 2005; Yuile, Dent, Cook, Biggs, &
Little, 2006;Yabroff et al.,2012). The prognosis of GBM remains poor despite ongoing
therapeutic advancements. Median survival from initial diagnosis is, at best,
approximately one year. Given the dismal prognosis, multimodal aggressive therapy
consisting of surgical resection of the GBM tumor, radiation therapy, and chemotherapy
administration is done in an attempt to prolong survival time. In an attempt to understand
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contributory factors associated with the development of GBM, studies have explored a
multitude of exogenous factors such as smoking, diet, cell phone use, ionizing radiation,
electromagnetic fields, immunological status, allergies, and viral infections just to name a
few. Unfortunately, there is no definitive evidence implicated in the development of
GBM except for prolonged exposure to ionizing radiation.
The difficulty in treating GBM is well recognized. Researchers have sought to
evaluate those factors that contribute to worsening survival times and/or prolonging
survival times. In order to optimize treatment modalities for individual patients, it is
critical to evaluate prognostic factors that will enhance survival. Data from the Glioma
Outcomes Project demonstrated that patient age, functional status, and complete resection
of the tumor were statistically significant prognostic indicators for patient survival (Laws
et al., 2003).
•

Age is the most significant prognostic factor for survival. It is noted that age
younger than 60 years is a favorable prognostic factor (Mineo et al., 2007;
Chandana, Movva, Arora, & Singh, 2008).

•

In an attempt to understand how well GBM patients are doing physically, medical
providers will assess their ability to carry out everyday activities, or their
functional capacity. There are different kinds of functional tests that practitioners
use to determine a patient’s level of functioning. One of the most commonly used
tests is identified as the Karnofsky Performance Scale (KPS) developed in 1949
by Karnofsky and Burchenal. A patient can score anywhere from 0 to 100, with 0
representing death while 100 is considered normal with no evidence of disease. A
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score of 80 or greater is considered a good prognostic indicator for GBM patients
(Stark, Stepper, & Medhorn, 2010).
•

Removal of the entire GBM tumor is impossible because of the hyper-vascularity
and invasiveness of the tumor. Therefore, surgeons strive to remove as much of
the tumor as possible to decrease the tumor size, relieve pressure on the brain
known as intracranial pressure (ICP), and prolong survival (Chandana et al.,
2008). Hentschel and Lang (2004) noted that aggressive resection where more
than 98 % of the GBM tumor is removed is associated with a statistically
significant improved survival rate.

•

Epilepsy or seizures represent a significant prognostic factor because it leads to
earlier diagnosis (Mineo et al., 2007; Chandana et al., 2008). However, there are
many GBM patients who never experience seizures.

•

Patients who present with acute onset or significantly disturbing symptoms show
improved survival when compared to patients who experience symptoms that are
subtle or slower to evolve (Yulie et al., 2006).
Summary
This chapter included a review of the literature pertinent to this study. I described

Andersen’s Health Behavioral Model which serves as the theoretical framework used for
this study. Additionally, this chapter included a discussion of the geographic variations
of GBM in the United States, the clinical attributes of GBM including its definition,
symptomatology, detection, prognostic characteristics, diagnosis, and treatment options
followed by the epidemiological characteristics of GBM from a person, place, and time
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perspective based on the most current literature. Major studies on GBM were reviewed
and summarized. Finally, analysis of this literature review highlighted a knowledge gap
regarding urban and rural variances in tumor size, treatment options, and survival rate in
GBM patients.
Almost 20 % of the population in the United States lives in a rural setting, are
generally older, usually unemployed, experience greater poverty, tend to be in poor
health, and are usually uninsured (Hart et al., 2005). Rural residents are challenged with
barriers when trying to access health care services such as traveling longer distances to
reach health care facilities, and have fewer doctors and hospitals than urban residents. By
the time rural residents do access the healthcare system, their health issues may be more
serious or far advanced. This study will help fill the knowledge gap related to geographic
variations in GBM tumor size, treatment options, and survival rate. Research that focuses
on early detection of GBM, increasing GBM awareness, and geographic variation has
received inadequate attention. This study may help to fill the void in the current state of
affairs related to GBM, and thereby lead to future research that will improve survival
rates in this deadly disease.
In Chapter 3, I discuss the study methodology that used to address the primary
research question: Are there differences in tumor size, treatment options, and survival
rate between urban and rural GBM patients? Chapter 3 describes the research design,
setting, sample and eligibility criteria. Additionally, Chapter 3 offers a thorough
discussion of instrumentation and materials, data collection, and analysis. Finally,
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Chapter 3 closes with a discussion on maintaining quality assurance and confidentiality,
and ensuring protection of human subjects.
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Chapter 3: Research Method
Introduction
In this study, I focused on patients 20 years and older who have been diagnosed
with GBM. My purpose was to determine if differences in tumor size, treatment options,
and survival rate occur in GBM patients living in urban versus rural regions of the United
States. This chapter delineated the research design, data setting, and sample. A
discussion of the research design section included the rationale for the design of the
study. The setting and sample section included a description of the study’s sample
population and criteria for inclusion. The instrumentation and materials section included
a discussion of the SEER database and cancer registries. The data collection and analysis
section addressed the research questions and study variables. The final section provided
a discussion of quality assurance, confidentiality of study subjects, and protecting human
research participants.
Research Design and Approach
This retrospective study explored the differences in GBM tumor size, treatment
options, and survival rate in urban versus rural patients. The independent variables were
urban (metropolitan) and rural (nonmetropolitan) areas. The dependent variables were
tumor size at diagnosis, treatment options (surgical resection and adjuvant therapies of
radiation treatment and chemotherapy), and survival rate. Using secondary data sets
available through the SEER program, this was a quantitative, retrospective cohort study.
The SEER Program is a division of the National Cancer Institutes (NCI) involved in the
collection of cancer data across the United States. Cancer data is collected by specially-
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trained personnel from 18 cancer registries representing 28% of the United States
population (SEER, 2013). The SEER registries consistently collect the following types
of data: patient information, type of cancer, primary location of the cancer or tumor,
tumor size, microscopic composition of the tumor, stage and grade of the tumor,
treatment options, and survival data (SEER, 2013). Once the data are collected, the data
are then analyzed for cancer trends in the United States, including cancer incidence for
specific cancers, population characteristics, treatment options, and survival and mortality
data.
The primary benefits of a retrospective cohort design are that it is less expensive,
easier to conduct, less prone to bias, and optimal for multiple outcomes analysis (Mann,
2003). Additionally, since the SEER database is linked to census data, researchers can
examine disease patterns across numerous demographic and socioeconomic variables
(SEER, 2013). A major disadvantage of a retrospective cohort design involves collection
of data prior to the study. For instance, failure to adhere to data standardization
procedures may lead to incomplete or erroneous entries. Another disadvantage of
retrospective cohort studies is the inability to control for confounding variables (Mann,
2003). Finally, retrospective cohort studies may be prone to bias given the manner in
which study subjects are selected and the potential for subjects to drop out of the study.
Setting and Sample
Adult patients 20 years of age and older diagnosed with GBM served as the study
population. Data were collected and analyzed retrospectively using the most recent
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SEER database covering the years 1973 through 2011. For the purposes of this particular
study, data were collected on GBM patients diagnosed from 1988 to 2011.
Eligibility Criteria
The sample consisted of subjects with the following eligibility characteristics: (a)
adults diagnosed with GBM, (b) age at diagnosis: all ages, (c) place of residence: urban
(metropolitan) or rural (nonmetropolitan), (d) year of diagnosis: 1988 to 2011 inclusive,
(e) race and ethnicity: all races and all ethnicities reported, (f) tumor size, (g) surgical
resection (yes/no), (h) adjuvant therapies: radiation treatment (yes/no) and chemotherapy
(yes/no), and (i) survival time: 5 years after diagnosis. The SEER database specifically
classifies tumors by a collaborative staging code most commonly referred to as a CS
code, and used to identify the part of the body where the tumor is found. CS codes
specific to GBM tumors corresponded to the particular lobe or area in the brain where the
tumor was located. The CS codes for GBM tumors included C70.0 and C71.0-71.9. See
Table 5 for location of brain tumors.
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Table 5
Brain/Cerebral Meninges
CS code
C70.0
C71.0
C71.1
C71.2
C71.3
C71.4
C71.5
C71.6
C71.7
C71.8
C71.9

Location
Cerebral meninges
Cerebrum
Frontal lobe
Temporal lobe
Parietal lobe
Occipital lobe
Ventricle, NOS*
Cerebellum, NOS*
Brain stem
Overlapping lesion of brain
Brain, NOS* (not otherwise specified)

Note. Beahrs, O. H., Henson, D. E., Hutter, R. V. P., & Kennedy, B. J.(1992). Manual for staging of
cancer (4th ed.). Philadelphia, PA: J. B. Lippincott Company.

Power Analysis
The power of a statistical test allows the researcher to decide the size of the
sample needed to produce accurate and reliable results. For this study, statistical power
was calculated using a priori power analyses conducted using *G Power. An a priori
analysis was done to ascertain the required sample size that will achieve a given
statistical power. More specifically, the statistical power of a test detected that a
phenomenon does in fact exist (Cohen, 1988; High, 2000).
For this study, the expectation was that the null hypothesis would be rejected for
all research questions noted in the following:
•

Research Question 1: There is no significant difference in GBM tumor size
between urban and rural patients.
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•

Research Question 2: There is no significant difference in the treatment option of
surgical resection.

•

Research Question 3: There is no significant difference in the adjuvant therapies
of radiation treatment and/or chemotherapy between urban and rural patients.

•

Research Question 4: There is no significant difference in GBM survival rates
between urban and rural patients.

•

Research Question 5: There is no significant difference in GBM survival rates
controlling for region, race, age, sex, educational, and family income in the study
population of GBM cases.
Using G*Power v3.1.0 to determine the sample size, the test family of t tests were

used. A calculation estimating the effect size was determined to be 0.32, or medium
effect, and a power of 0.80 was selected. Power analysis was done by entering the
proportions for the null hypotheses (rural patients diagnosed with GBM will not present
with larger tumor, limited treatment options, or have poorer survival) against proportions
expected to be seen. The G*Power Analysis calculator, developed by Faul, Erdfelder,
Lang, and Buchner (2007) was set at the test family of t tests using the Mann-Whitney U
test , the a priori total sample size was calculated at 256 (equal sample size in urban and
rural groups). Table 6 shows the G*Power Analysis Calculator.
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Table 6
G*Power Analysis Calculator (a priori) Independent Samples t Test Using the MannWhitney U test
Input
Effect size w
α err prob

Calculation
0.32
0.5

Power (1-β err prob)
Allocation ratio N2/N1
Input
Noncentrality parameter λ
Critical t
Sample size group 1
Sample size group 2
Df
Total sample size
Actual power

0.80
1
Calculation
2.5016449
1.6511624
128
128
242.462
256
0.8022824

Note. To calculate the sample size for the Kaplan Meier and Cox Proportional Hazard
Ratio, the MedCalc version 12.7.7 (Medcalc Software, 2013) was used. The a priori
sample size was calculated at 196 (equal sample size in urban and rural groups).
Table 7
Survival Analysis (logrank test): MedCalc (a priori): Compute Required Sample Size
Options
Type I error (alpha, significance)
Type II error (Beta, 1-Power)

0.05
0.20

Data
Survival rate Group 1
Survival rate Group 2
Ratio of Sample Sizes in Group1/Group 2

0.6
0.4
1

Result
Number of cases required in Group 1
Number of cases required in Group 2
Total sample size (both groups together)

98
98
196
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Data Collection and Analysis
The SEER Program provided a cancer database considered the preeminent source
of cancer-specific and population statistics for the United States (SEER, 2013). In
addition to cancer-specific data, the SEER database captured population-based data like
gender, race/ethnicity, age, date of original diagnosis, the geographic location of
residence, patient-specific treatments, tumor stage and size, and patient survival data
(SEER, 2013). The advantages of using the SEER database included the following: (a) It
is a relatively inexpensive way to obtain cancer-specific data; (b) its validity and
reliability has been established; and (c) its comprehensiveness lends itself to obtaining a
large sample size with increased power. Data were manually extracted from the SEER
database using SPSS (IBM Statistics Grad Pack Version 20). SPSS has the capability of
handling sizeable datasets and the ability to perform data analysis employing an
assortment of statistical tests.
This retrospective cohort study used secondary data obtained from the 1973-2011
SEER database to examine the relationship between GBM cases in urban and rural areas,
tumor size, functional status, and survival. The data were publically available and readily
accessible by signing a SEER Research Data Agreement (SEER, 2013). This agreement
stressed the importance of protecting the identities of cancer patients covered in the
Protection of Human Subjects. Data can be accessed via the Internet or on a DVD. For
this study, a request was made to have access to the data and SEER*Stat software via the
Internet. A personalized SEER Research Data Agreement was generated and signed, and
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permission to access the data was granted (refer to Appendix A). After permission was
granted, a confidential and unique user name and password were assigned by SEER.
All GBM cases noted earlier were assigned to regions and dichotomized to urban
and rural counties based on location of residence when diagnosed. To further understand
the regional variations, the study evaluated tumor size at diagnosis, the treatment option
of surgical resection, adjuvant therapies of radiation treatment and chemotherapy, and
survival rate. Five research questions were evaluated:
•

Research Question 1: When comparing urban and rural patients with GBM, is
there a significant difference in GBM tumor size at diagnosis?

•

Research Question 2: When comparing urban and rural patients with GBM, is
there a significant difference in the number of GBM patients who experience
surgical resection?

•

Research Question 3: When comparing urban and rural patients with GBM, is
there a significant difference in the number of GBM patients who experience
adjuvant therapies of radiation treatment and chemotherapy?

•

Research Question 4: When comparing urban and rural patients with GBM, is
there a significant difference in GBM survival rates?

•

Research Question 5: In the study population of GBM patients, is there a
significant difference in survival rates when controlling for region, race, age, sex,
educational level, and median family income?

Inclusion criteria included all GBM cases diagnosed in adults 20 years and older reported
to SEER between 1988 and 2011. Data on stage at diagnosis have been reported since
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1975. However, tumor size has only been reported since 1988 (Farrow, Samet, & Hunt,
1996). Consequently, the SEER data were scrutinized for all GBM cases diagnosed from
1988 through 2010 inclusive of data on tumor size.
Independent Variable
The independent variable for this study is identified as region, apportioned to
urban and rural counties. In the SEER database, two other terms describe urban and
rural: Metropolitan was used interchangeably with urban, and nonmetropolitan was used
interchangeably with rural. The independent variable of region was presumed to
influence the dependent variables noted below. The geographic features of urban and
rural areas may be critical in accessing healthcare resources, early screening and
detection, and providing basic preventive health services (Klein, 2010). Rural
populations have poorer access to healthcare facilities and resources that may affect not
only access to healthcare in general but also access to preventive cancer screening and
specialized health services. Consequently, rural residents will not seek care at the time of
need, and when care is finally sought, rural patients are found in advanced disease stages
than their urban counterparts (Eberhardt et al., 2002). Complicating this scenario is the
fact that rural residents face longer distances and travel times to medical facilities
including cancer centers, treatment facilities, and specialized providers (Coughlin et al.,
2002).
Dependent Variables
This study addresses four dependent variables: tumor size, surgical resection,
adjuvant therapies of radiation treatment and chemotherapy, and survival rate. Past

53
research identified these variables as prognostic indicators for adults diagnosed with
GBM. GBM is usually diagnosed at an advanced stage known as a Grade 4 tumor. Grade
4 tumors are usually larger in size than early-stage tumors. Larger tumors and advanced
age at diagnosis are associated with a lower survival rate.
Scales of Measurement
The level of measurement of the independent variable of region apportioned to
urban and rural was nominal. There were four dependent variables for this study: tumor
size at initial diagnosis, surgical resection, adjuvant therapies of radiation treatment and
chemotherapy, and survival rate. The level of measurement for tumor size was ordinal
since the SEER database uses categories of tumor size ranges where tumor size is
measured in centimeters. Ordinal measurements assign observations into categories that
can be put into rank order and do not quantify differences (Gerstman, 2008, p. 5). Since
rank orders do not quantify differences, conditions of normality and equal variance are
absent. Thus, a nonparametric statistic was be used. Data analysis for the first research
question used the Independent Samples t test or Mann-Whitney U test, depending on
normality. The level of measurement for surgical resection as reflected by whether or not
the patient experienced surgical resection was nominal, and correlated to a simple
classification of yes versus no. Data analysis for the second research question involving
surgical resections was conducted using the Independent Samples t test or the MannWhitney U test depending on sample size and normality. The level of measurement for
adjuvant therapies of radiation treatment and chemotherapy as reflected by whether or not
the patient experienced radiation treatment (yes/no) and/or chemotherapy (yes/no) was
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nominal, and correlated to a simple classification of yes versus no for each adjuvant
therapy of radiation treatment and chemotherapy. The fourth research question on
survival rate used two statistical tests. First, the Kaplan-Meier was used for univariate
analysis. Second, the Cox proportional hazards (regression analysis) was used for
multivariate analysis of survival differences between groups (urban and rural). The fifth
research question involving survival rates used multiple regression modeling to determine
the best predictive model based on the independent variables of region, gender, race, age,
marital status, education, and family income in the study population of GBM cases
(Klein, Ji, Rea, & Stoodt, 2011). Table 8 shows the multiple regression modeling and
associated independent variables.

55
Table 8
Variables for Multiple Regression Modeling
Variables
Race
Black
White
Other
Unknown
Marital status
Single
Married
Widowed
Divorced/Separated
Education level
Low
Medium
High
AGE
< 50
50-70
71-80
> 80
Median family income
< $50,000
$51,000 - $64,000
> $65,000

Rural (n)

Rural %

Urban (n)

Urban %

Total

Instrumentation and Materials
The database used is the SEER Program of the National Cancer Institute (NCI)
(SEER, 2013). A plethora of data is collected from 18 cancer registries across the United
States, as noted in the data collection and analysis section. The registries noted in Table
9 correspond to their geographic location:
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Table 9
SEER 18 Registries
Alaska Native Tumor Registry
Arizona Indians
Cherokee Nation
Connecticut
Detroit
Georgia Center for Cancer
Greater Bay Area Cancer Registry
Greater California
Hawaii
Iowa
Kentucky
Los Angeles
Louisiana
New Jersey
New Mexico
Seattle-Puget Sound
Utah
Note. SEER (n.d.). List of SEER registries. Washington, D.C.: United States Department of Health and
Human Services. Retrieved from http://seer.cancer.gov/registries/list.html. Information is in the public
domain. Permission to reproduce not required.

The above noted geographic regions represented 28% of the United States
population, and accounted for a broad cross section of the population representing
different ethnicities, cultures, and geography (National Cancer Institute, 2010). While
the entire United States was not represented in the SEER database, the coverage was
broad enough to account for the many population groups living in the United States
(SEER, 2010). For the purposes of this study, all of these regions identified in the SEER
database were used for data collection, and then categorized into urban and rural areas
using RUCCs. Figure 7 shows the location of SEER registries across the United States.
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Figure 7. Locations of SEER registries across the United States
Note. SEER (n.d.). About the SEER registries. Washington, DC: United States Department of Health and
Human Services. Retrieved from http://seer.cancer.gov/registries/. Figure is in the public domain.
Permission to reproduce not required.

The 18 population-based registries fall under the auspices of the North American
Association of Central Cancer Registries (NAACCR). The NAACCR provides guidance
in data collection to all registries as a way of maintaining the integrity, quality, and
accuracy of collected data (National Cancer Institute, n.d.). The NAACCR has a rigorous
audit and quality control process to ensure the accuracy of collected data (National
Cancer Institute, n.d.), and study results are ultimately used to improve documentation of
data (National Cancer Institute, n.d.).
In addition to state and regional registries, the SEER Program interfaces with
other federal and state agencies as well as nationally-recognized databases for research

58
purposes. For example, the National Center for Health Statistics provides mortality
statistics, and the Census Bureau provides population data for the calculation of cancer
rates (National Cancer Institute, n.d.). SEER also works with the Centers for Medicare
and Medicaid Services (CMS) to collect data on cancer statistics in the elderly. Finally,
SEER has joined forces with the National Longitudinal Mortality Study (NLMS) to
explore cancer incidence, tumor characteristics, and survival rates from a socioeconomic
and demographic perspective.
Quality Assurance
The SEER database is considered the model of excellence for data quality, and
often referred to as the gold standard for data collection. Quality improvement is critical
to enhancing and continuously improving data quality. Quality improvement activities
include case-finding audits related to data collection procedures, reliability studies that
test the skills of registry personnel, and reabstraction studies at central and hospital
cancer registries to continuously improve the input of meaningful data. To safeguard all
study-related materials and maintain confidentiality, data were secured on a passwordprotected laptop with anti-virus software and internal firewalls. All study files were
backed up daily, and saved on a password-protected flash memory card (thumb drive)
maintained in a locked file cabinet. The researcher was the only person with access to the
laptop, thumb drive, and key to the file cabinet.
Protection of Human Subjects
This study used secondary data sets from the SEER database. All data were deidentified as noted in the Privacy Rule which evolved from the Health Insurance
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Portability and Accountability Act (HIPAA) of 1996. Additionally, the SEER registry
program requires the researcher to sign a Limited Use Agreement in order to grant access
to the data (Appendix A). Finally, an application for study approval was submitted to the
Institutional Review Board (IRB) of Walden University (IRB approval # 01-28-140174231). Data collection and analysis moved forward once final approval was received
from the IRB.
Dissemination of Findings
Dissemination of research findings is a critical component of any study. Equally
important is Walden University’s commitment to social change. Therefore, synthesis and
dissemination of research findings for this study provides relevant and valid research
evidence and implications for social change to colleagues, clinicians, and health policy
makers.
Summary
Chapter 3 provided the basic methodology of this quantitative retrospective cohort
study. The research design and approach provided the systematic plan to study GBM
patients in urban and rural regions in relationship to tumor size, treatment options, and
survival rate. The sample population was identified, including a thorough description of
the eligibility criteria. The selected instrumentation and materials provided a
comprehensive examination of the data sources associated with the SEER registries.
Data collection and analysis provided the context for the established research questions,
independent and dependent variables and their associated levels of measurement. Quality
assurance focused on confidentiality, and the protection of human subjects provided
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context around the Privacy Rule which grew out of HIPAA, the limited-use data
agreement required by SEER, and subsequent IRB approval through Walden University.
The methodology for this study was used to determine if urban and rural GBM patients
experience differences in tumor size at diagnosis, surgical resections, adjuvant therapies
of radiation treatment and chemotherapy, and survival rates using the U.S. SEER
database. Study results are covered in Chapter 4.
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Chapter 4: Results
The purpose of this retrospective, quantitative study was to ascertain if there are
differences in tumor size, treatment options, and survival rates between rural and urban
patients diagnosed with GBM. Research Question 1: Was there a potential relationship
of GBM tumor size in urban and rural patients? Research Question 2: Was there a link
between the treatment option of surgical resections in urban and rural patients? Research
Question 3: Was there a relationship between treatment options of radiation therapy and
chemotherapy in urban and rural patients? Research Question 4: Were there differences
in survival rates of urban and rural patients. Research Question 5: Were there differences
in survival rates of urban and rural patients when controlling for region, race, age, sex,
educational level, and median family income? The hypothesis under review is that rural
patients diagnosed with GBM will present with larger tumor size, experience fewer
treatment options of surgical resections, radiation therapy, and chemotherapy, and have
poorer survival rates compared to urban patients diagnosed with GBM.
I begin this chapter with a detailed description of data collection methods and any
discrepancies from the outlined plan provided in Chapter 3. Next, descriptive statistics
are provided for every variable of the study population. Finally, all statistical analyses
specific to each research question are explained in detail.
Data Collection
This retrospective cohort study used secondary data obtained from the 1973 to
2011 SEER 18 database to examine the relationship between GBM cases in urban and
rural areas, tumor size, treatment options, and survival. The SEER Program provides a
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cancer database, which is the premier source of cancer-specific and population statistics
associated by age, race/ethnicity, year of diagnosis, and geographic areas in the United
States. Additionally, it is the only comprehensive source of population-based data in the
United States that documents tumor size at diagnosis and survival data (SEER, 2013).
The SEER 18 Registries of the NCI collects and analyzes cancer incidence, prevalence,
and survival data from 18 population-based cancer registries covering approximately
28% of the total U.S. population (SEER, 2013). Refer to Table 9 in Chapter 3 for a
complete listing of the registries. While the entire United States is not represented in the
SEER database, the coverage is broad enough to account for the various diverse
populations throughout the United States (SEER, 2010).
Using the SEER 18 database, cases were selected specific to this study that
included all adults greater than 20 years old diagnosed with GBM in the United States
between 1988 and 2011. This selection resulted in 33,202 eligible cases. Permission to
view the selected cases was granted by both the Walden University IRB approval # 0128-14-0174231 and the SEER Program.
Demographic information collected for this analysis included the following: a
unique patient identifier, age, gender, race, marital status, registry location, location of
residence categorized by either urban or rural area, median family income, educational
level (< 9th grade, high school, or bachelor’s degree), GBM tumor size in millimeters,
whether or not the patient underwent surgical resection of the brain tumor (yes/no),
whether or not the patient underwent radiation therapy (yes/no), and survival time noted
in months. It should be noted that data for the adjuvant therapy of chemotherapy
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administration were going to be obtained from the SEER database. Unfortunately, these
data were no longer included in the SEER database made available to the public. This
will be further explained in Chapter 5. Since this was a retrospective study where deidentified patient information was used, informed consent was not required.
The study sample of 33,202 patients appears to exhibit appropriate external
validity in that the sample consisted of patients representing all 18 registries of the SEER
database. Furthermore, the sample includes both males and females diagnosed with
GBM as well as all races, 20 years and older, representing urban and rural areas. It is
worth noting that there are no studies to date that have examined the demographic
variables of GBM from the geographic perspective of urban versus rural locations. As
described in the following results section, descriptive statistics appropriately examined
the study sample, and inferential statistics explored the aforementioned research
questions and associated hypotheses.
Demographic Results
Initially, a series of descriptive statistics was conducted on these data to
summarize characteristics of the study population. First, Figure 8 shows the number of
GBM cases diagnosed from 1988 through 2011 in the United States. In general,
diagnosed cases have increased annually with a sharp spike in 2000.

64

Figure 8. Glioblastoma multiforme cases diagnosed in the United States from the SEER data
base, 1988-2011.

The sample included 12,430 females (37.44%) and 20,772 males (62.56%). As shown in
the following table, the vast majority of the sample was white (91%), followed by black
(5.14%) and other (4.19%). Finally, less than 1% of respondents did not have valid data
on race.
Table 10
Percent Distribution of Study Subjects by Race (N = 33,202)
Category
Black
Other
White
Unknown
Total

N
1,706
1,391
30,049
56
33,202

%
5.14
4.19
90.50
0.17

Table 11 summarizes the descriptive statistics conducted focusing upon respondent age.
As shown, a broad range in responses was found, with the majority of patients being
between the ages of 50 and 74.
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Table 11
Frequency Distribution of Study Subjects by Age. (N = 33,202)
Category
20-24 years
25-29 years
30-34 years
35-39 years
40-44 years
45-49 years
50-54 years
55-59 years
60-64 years
65-69 years
70-74 years
75-79 years
80-84 years
85+ years
Total

N
215
371
520
873
1,545
2,576
3,586
4,364
4,771
4,434
4,134
3,260
1,816
737
33,202

%
0.65
1.12
1.57
2.63
4.65
7.76
10.80
13.14
14.37
13.35
12.45
9.82
5.47
2.22
100.00

Table 12 summarizes the descriptive statistics conducted with relation to marital status at
time of diagnosis. Slightly over 76% of the sample was found to be married, with
slightly over 9% being divorced. Slightly over 13% of respondents were single/never
married, with close to 1% being separated.
Table 12
Frequency Distribution of Study Subjects by Marital Status (N = 33,202)
Category
Divorced
Married
Separated
Single (never married)
Total

N
3,134
25,308
286
4,474
33,202

%
9.44
76.22
0.86
13.48
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Table 13 summarizes from which registry location these data were derived. As
shown, a very wide range was found with regard to the source of these data, suggesting
that while not a probability sample, these data are representative of a broad population of
patients. With respect to region, 29,140 (88.29%) patients lived in urban (metropolitan)
regions, while 3,864 (11.71%) live in rural (nonmetropolitan) regions.
Table 13
Frequency Distribution of Study Subjects by Location of Registry
Category
Alaska Natives - 1992+
Atlanta (Metropolitan) - 1975+
California excluding SF/SJM/LA - 2000+
Connecticut - 1973+
Detroit (Metropolitan) - 1973+
Greater Georgia - 2000+
Hawaii - 1973+
Iowa - 1973+
Kentucky - 2000+
Los Angeles - 1992+
Louisiana - 2000+
New Jersey - 2000+
New Mexico - 1973+
Rural Georgia - 1992+
San Francisco-Oakland SMSA - 1973+
San Jose-Monterey - 1992+
Seattle (Puget Sound) - 1974+
Utah - 1973+
Total

N

%

19
1,179
6,005
2,397
2,213
1,681
418
2,118
1,254
3,476
1,214
2,843
809
61
2,560
1,132
2,690
1,133
33,202

0.06
3.55
18.09
7.22
6.67
5.06
1.26
6.38
3.78
10.47
3.66
8.56
2.44
0.18
7.71
3.41
8.10
3.41
100.00

Table 14 summarizes the descriptive statistics conducted with regard to all continuous
measures of interest included within the data. This consisted of tumor size, median
family income measured in $10,000s, the percentage of the population with less than a
high school degree, the percentage with a bachelor's degree or above, survival (measured
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in months), and year of diagnosis. Mean scores were focused upon as a measure of
central tendency for these measures, as mean and median scores were found to be very
similar with the exception of survival time. Mean tumor size is measured in millimeters
and relates to a new measure that combined the two initial measures of tumor size after
having removed all missing and invalid data. Average tumor size was found to be close
to 34 mm. Next, with regard to median family income, this was found to be close to
$73,000. The percentage of individuals with less than a high school degree was found to
be close to 15%, with the percentage having at least a bachelor's degree found to be close
to 31%. Mean survival time was close to 12 months with a median of 7 months.
Table 14
Frequency Distribution of Study Subjects by Continuous Measures
Measure
Tumor Size (mm)
Family Inc. (in $10k)
% less than High School
% at least BA Degree
Survival (Months)

Valid N

Mean

33202
33201
33201
33201
33176

33.553
7.267
14.885
30.591
11.824

Median
36
6.948
13.52
29.61
7

SD
37.418
1.700
6.180
10.226
18.361

Min

Max

0
2.565
1.390
45.90
0

989
12.381
43.89
63.94
287

Additionally, Table 15 looks at the sociodemographic variables of race, marital status,
educational level, age, and median family income by rural and urban regions.
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Table 15
Frequency Distribution of Study Subjects by Sociodemographic Characteristics
Variables

Rural (N)

Rural %

Urban (N)

Urban %

Total

Race
Black
White
Other
Unknown
Total

126
3779
155
2
4062

7.39%
12.58%
11.14%
3.57%
12.2%

1580
26270
1236
54
29140

92.61%
87.42%
88.86%
96.43%
87.8%

1706
30049
1391
56
33202

Marital status
Single
Married
Divorced
Separated

392
3286
360
24

8.76%
12.98%
11.49%
8.39%

4082
22022
2774
262

91.24%
87.02%
88.51%
91.61%

4474
25308
3134
286

–
–
–

64.22%
15.88%
18.97%

–
–
–

69.55%
14.75%
32.21%

–
–
–

Age
< 50
51-70
71-80
> 80

635
2099
1018
310

10.41%
12.24%
13.77%
12.14%

5465
15056
6376
2243

89.59%
87.76%
86.23%
87.86%

6100
17155
7394
2553

Median family
income
< $50,000
$51,000 - $64,000
> $65,000

1325
1908
828

63.04%
17.40%
4.11%

777
9060
19303

36.96%
82.60%
95.89%

2102
10968
20131

Education level
Low
Medium
High

Finally, several new measures were constructed for the purpose of these analyses.
With regard to surgical resection, 8,709 (26.23%) patients did not receive resection, while
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24,493 (73.77%) did. Regarding radiation, 8,075 (24.80%) patients did not receive
radiation therapy, while 24,484 (75.20%) did.
Research Questions and Hypotheses Results
Research Question 1: Results
Research Question 1: When comparing urban and rural patients with GBM, is
there a significant difference in GBM tumor size at diagnosis?
H01: When comparing urban and rural patients with GBM, there is no significant
difference in GBM tumor size.
H11: When comparing urban and rural patients with GBM, there is a significant
difference in GBM tumor size.
In order to test the first research question, initially, measures of skewness and
kurtosis indicated strong nonnormality with respect to tumor size. However, the very
large sample size present in this data set would make nonnormality less important with
respect to an independent samples t test; for this reason, both a t test as well as a MannWhitney U test was conducted in order to test this research question. In these analyses,
tumor size at the time of diagnosis was analyzed as the outcome measure of interest, with
regional status included as the dichotomous predictor variable.
First, Table 16 summarizes the descriptive statistics associated with the MannWhitney U test. As shown, moderate differences were present when comparing the rank
sums and expected values. This test itself was found to achieve statistical significance, z
= -2.632, p = .0085. These results indicate that patients residing in rural areas had a
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significantly larger mean tumor size as compared with those residing in urban regions.
Therefore, the null hypothesis is rejected.
Table 16
Descriptive Statistics of Urban/Rural Areas Using the Mann-Whitney U test
Category

Valid N

Ranksum

Expected

Urban
Rural
Combined

29140
3864
33004

4.794E8
65212919
5.446E8

4.809E8
63765660
5.446E8

Next, Table 17 summarizes the descriptive statistics associated with the independentsamples t test conducted. Again, these results indicate a higher mean tumor size with
regard to individuals residing in non-metropolitan regions. The independent-samples
t test also achieved significance, t (33002) = -2.3722, p = .018. Therefore, the null
hypothesis is rejected.
Table 17
Descriptive Statistics of Urban/Rural Regions Using the Independent-Samples t-test
Category

Valid N

Mean

SD

Urban
Rural
Combined
Difference

29140
3864
33004

33.391
34.913
33.569
-1.522

.215
.682
.206
.641
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Research Question 2: Results
Research Question 2: When comparing urban and rural patients with GBM, is
there a significant difference in the number of patients who experienced surgical
resections?
H02: When comparing urban and rural patients with GBM, there is no significant
difference in the number of patients who experienced surgical resections.
H12: When comparing urban and rural patients with GBM, there is a significant
difference in the number of patients who experienced surgical resections.
Initially, a new measure was created which consisted of a dummy measure of
whether or not respondents had a surgical resection. In the overall sample of 33,202
patients, 24,493 (73.8%) had a surgical resection, while 8,709 did not (26.2%). A chisquare analysis was then conducted to determine if a significant association existed
between these two measures. First, Table 18 presents the cross tabulation conducted
between these two measures. As shown, no distinct relationship is apparent.
Table 18
Cross Tabulation Results Between Surgical Resection and Regional Status

Region
Category
Urban
Rural
Total

Resection
No

Yes

Total

7617
1032
8649

21523
2832
24355

29140
3864
33004
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Second, the chi-square analysis conducted in relation to this hypothesis also failed to
achieve statistical significance, χ2 (1) = .5707, p = .450. Therefore, the null hypothesis is
accepted.
Research Question 3: Results
Research Question 3: When comparing urban and rural patients with GBM, is
there a significant difference in the number of patients who experienced the adjuvant
therapies of radiation treatment and chemotherapy?
H03: When comparing urban and rural patients with GBM, there is no significant
difference in the number of patients who experienced the adjuvant therapies of radiation
treatment and chemotherapy.
H13: When comparing urban and rural patients with GBM, there is a significant
difference in the number of patients who experienced the adjuvant therapies of radiation
treatment and chemotherapy.
For this research question, initially, a new variable was constructed which
consisted of a dummy variable measuring whether patients received radiation treatment.
This measure was coded 1 for patients that received any kind of radiation therapy
including the categories of beam radiation, combination of beam with implants or
isotopes, radiation NOS method or source not specified, radioactive implants, and
radioisotopes, and was coded 0 in cases of no radiation, and missing if responses to this
question were refused. Out of this sample of 32,366 patients, it was found that 24,333
(75.2%) patients received radiation therapy while 8,033 (24.8%) patients did not receive
radiation therapy. The use of radiation was slightly more common among patients
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residing in urban regions compared to rural areas. The chi-square analysis conducted is
found to achieve statistical significance, χ2 (1) = 18.3962, p < .001. Therefore, the null
hypothesis is rejected. See Table 19.
Table 19
Frequency Distribution of Study Subjects Comparing Radiation Therapy by Region
Region

Radiation

Category
Urban
Rural
Total

No
6987 (24.4%)
1046 (27.6%)
8033 (24.8%)

Yes

Total

21596 (75.6%)
2737 (72.4%)
24333 (75.2%)

28583
3783
32366

Research Question 4: Results
Research Question 4: When comparing urban and rural patients with GBM, is
there a significant difference in survival rates?
H04: When comparing urban and rural patients with GBM, there is no significant
difference with survival rates.
H14: When comparing urban and rural patients with GBM, there is a significant
difference in survival rates.
Of the overall sample of 33,176 patients, 4,056 (12.2%) rural patients survived
10.3 months while 29,120 (87.8%) urban patients survived 12.04 months as seen in Table
20.
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Table 20
Frequency Distribution of Study Subjects by Survival Time in Months
Category
Rural
Urban
Total

N

Mean

SD

4,056
29,120
33,176

10.286
12.039

16.119
18.642

Survival data is commonly depicted with a Kaplan-Meier curve noted in Figure 10. To
further explore this fourth research question, a Cox regression was conducted in which
region was used to predict survival time. This analysis again incorporated a total of
33,176 cases with the same number of failures and a total time at risk of 392,283 months.
Urban region was found to achieve statistical significance, with a hazard ratio of .882
(robust SE = .015), p < .001, 95% CI = [.853, .913]. Additionally, this regression model
was found to achieve statistical significance, Wald χ2 (1) = 52.94, p < .001. Therefore,
the null hypothesis is rejected as noted in Figure 9..
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Figure 9. Kaplan-Meier survival estimates for urban (metro) and rural (nonmetro)
GBM patients.
Research Question 5: Results
Research Question 5: In the study population of GBM patients, is there a
significant difference in survival rates when controlling for region, race, age, sex,
educational level, and median family income?
H05: In the study population of GBM patients, when controlling for region, race,
age, sex, educational level, and median family income, there is no significant difference
in survival rates.
H15: In the study population of GBM patients, when controlling for region, race,
age, sex, educational level, and median family income, there is a significant difference in
survival rates.
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In this analysis, the measures of region, race, age, gender, educational level, and
median family income were included as predictors of the number of survival months.
Since the data on the total number of survival months were found to be strongly
positively skewed, a negative binomial regression was used for this analysis.
Specifically, the predictors noted above included a dummy variable representing regional
status, dummy variables representing blacks as well as individuals of other race and
individuals whose race was unknown, a dummy variable representing females, along with
age, the percentage of individuals with less than a high school education, the percentage
with at least a bachelor’s degree, as well as median family income measured in $10,000s,
which were all included as continuous measures.
The results of the analysis found statistical significance with respect to the effects
of regional status, age, gender, and median family income. Significantly longer survival
time was associated with urban status, female patients, and higher median family income.
Additionally, greater age was associated with significantly reduced survival time. This
overall regression model was found to achieve statistical significance, with a pseudo R2
of .0302. Therefore, the null hypothesis is rejected. See Table 21.
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Table 21
Negative Binomial Regression Results When Controlling for Region, Race, Age, Gender,
Education, and Family Income
Variable
Urban Region
Race: Black
Race: Other
Race: Unknown
Age
Female
% Less than High School
% At Least BA
Median Family Income
Constant

Coefficient

SE

z

p

.058
- .050
.043
.095
- .189
.076
.001
- .001
.035
3.692

.020
.026
.029
.140
.002
.012
.001
.001
.007
.048

2.85
-1.88
1.46
0.68
-83.65
6.35
1.14
-0.67
5.28
76.31

0.004
0.060
0.143
0.500
0.000
0.000
0.254
0.501
0.000
0.000

Note. N = 33175; LR χ2(9) = 7005.49, p < .0001; Pseudo R2 = 0.0302; Log likelihood = 112567.38; Likelihood-ratio test of α = 0: χ2(1) = 3.1E5, p >= χ2 < .001.
Summary and Transition
This study examined if there were differences in tumor size, treatment options,
and survival rates between rural and urban residents diagnosed with GBM. With regard
to tumor size, the results of this study indicated a significant difference in tumor size at
diagnosis between rural and urban GBM cases; that is, rural GBM patients presented with
significantly larger tumors at diagnosis. Therefore, the null hypothesis was rejected.
Treatment options of patients undergoing surgical resection, radiation therapy, and
chemotherapy were explored. There were no significant differences observed in rural
and urban GBM patients undergoing surgical resections. Therefore, the null hypothesis
was accepted. On the other hand, there were significant differences in urban GBM
patients undergoing radiation therapy compared to their rural counterparts. Therefore, the
null hypothesis was rejected. It was also noted that the chemotherapy variable could not
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be measured as it was removed from the SEER 18 database. The survival rate of GBM
patients in rural and urban areas was found to be statistically significant; that is, GBM
patients in rural areas have a poorer survival rate than GBM patients in urban areas.
Therefore the null hypothesis was rejected. In the final analysis, the survival rate was
examined in relationship to region, race, age, gender, educational level, and median
family income. Significantly longer survival times were noted with living in urban
regions, being female, and higher median family income. Additionally, greater age was
associated with significantly reduced survival time. The overall regression model was
found to be statistically significant. Thus, the null hypothesis was rejected.
Chapter 4 included the results of this quantitative, retrospective study that
examined the differences in tumor size, treatment options, and survival rate in rural and
urban patients diagnosed with GBM. Chapter 5 will include a further discussion on the
results by providing an interpretation of the observed findings, and how the findings
relate to current literature and within the context of the proposed theoretical foundation.
In Chapter 5, I will also outline the strengths and limitations of this study, as well as
provide recommendations for future research. Finally, in Chapter 5, I will discuss the
potential impact for making positive social change.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this quantitative, retrospective study was to determine if there
were differences in tumor size, treatment options, and survival rates between rural and
urban residents diagnosed with GBM. Patients who receive a GBM diagnosis barely
survive a year beyond the original diagnosis. Studies have not identified any consistent
links between possible risk factors and the development of GBM despite the rising
incidence of GBM (Bondy et al., 2008; Connelly & Malkin, 2007; Gomes et al., 2011).
While there is a plethora of research specific to GBM from environmental and genetic
influences, very little research has examined GBM from a regional perspective. This
project is unique in that examining patients diagnosed with GBM from an urban-rural
perspective has never been done before, highlighting a significant gap in the literature.
Using the SEER 18 database covering the years 1973 to 2011, this study used
secondary data sets of GBM cases reported between 1988 and 2011. Tumor size was
measured in millimeters, treatment was evaluated by ascertaining the number of GBM
patients who experienced surgical resection of their tumors and adjuvant therapies of
radiation and chemotherapy, and survival rate was evaluated using Kaplan-Meier curves
and Cox Regression analysis. With a sample size of 33,202 cases, data were obtained
and examined using descriptive and multivariable analyses of data with SPSS. Using the
Mann-Whitney U test and the independent samples t test, results showed statistically
significant differences in tumor size at diagnosis in rural patients compared to urban
patients (p = 0.0085; p = 0.018); that is, rural GBM patients had significantly larger
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tumor size at diagnosis compared to urban GBM patients. Furthermore, more urban
GBM patients were treated with radiation compared to their rural counterparts (p <
0.001). Additionally, rural GBM patients had poorer survival rates than urban GBM
patients (p< 0.001). Finally, when controlling for region, race, age, gender, educational
level, and median family income, a negative binomial regression analysis showed
significantly longer survival time was associated with urban status, female patients, and
higher median family income (Pseudo R2 = 0.0302; p < 0.0001). Moreover, greater age
was associated with significantly reduced survival time (Pseudo R2 = 0.0302; p <
0.0001).
Interpretation of the Findings
When comparing the results of this study to previous findings identified in the
Literature Review found in Chapter 2, the descriptive data appear to confirm prior
research. However, as noted previously, this study was unique in that examining patients
diagnosed with GBM from an urban-rural perspective has never been done before.
Therefore, this study’s results provide new knowledge in the GBM arena outlined below.
Descriptive Data
As discussed previously, while primary malignant brain tumors are rare in the
United States compared to other types of cancer (American Cancer Society, 2012a), there
is an increasing incidence of brain cancer reported for the last 3 decades (Deorah et al.,
2006). Figure 9 in Chapter 4 showed an increase in GBM incidence from 1988 to 2011.
Furthermore, while Aldape et al. (2003) found that GBMs are 1.6 times more common in
men than women, this study found GBMs are 1.7 times more common in men than
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women. Additionally, as in the study by Ohgaki and Kleihues (2005), this study
confirmed that glioblastomas are significantly higher among Whites as compared to
Blacks, American Indians and Alaskan natives, and Asian-Pacific Islanders race groups.
As in other peer-reviewed studies, the results of this study confirm that glioblastomas are
more common in older adults, and increase with age with primary occurrence in adults
from 45 to 70 years old (National Cancer Institute, 2012). Finally, with regard to
survival, the median survival time for a newly diagnosed GBM patient is approximately 1
year (Aldape et al., 2003) compared to slightly less than 1 year in this study.
Research Question 1: Tumor Size
In this study, I tested the hypotheses associated with the following research
question: When comparing urban and rural patients with GBM, is there a significant
difference in GBM tumor size at diagnosis?
H01: When comparing urban and rural patients with GBM, there is no significant
difference in GBM tumor size.
H11: When comparing urban and rural patients with GBM, there is a significant
difference in GBM tumor size.
In order to test this first research question, initially, measures of skewness and
kurtosis indicated strong nonnormality with respect to tumor size. However, the very
large sample size present in this data set would make nonnormality less important with
respect to an independent samples t test; for this reason, both a t test as well as a MannWhitney U test were conducted in order to test this research question. In these analyses,
tumor size at the time of diagnosis was analyzed as the outcome measure of interest, with
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regional status included as the dichotomous predictor variable. Both tests showed
statistically significant differences in tumor size in rural GBM patients compared to urban
GBM patients (Mann-Whitney, p= 0.0085; independent samples t test, p= 0.018); that is,
rural patients presented with larger GBM tumors than urban GBM patients. This resulted
in the rejection of the null hypothesis. To date, no other studies have explored GBM
tumor size from this urban-rural perspective. Several studies have suggested that rurality
is a risk factor in presenting with larger tumor size in other cancers including breast, lung,
cervical, and prostate cancers (Obertova, Brown, Holmes, & Lawrenson, 2011; Smaliyte
& Kurtinaitis, 2008; Westeel et al., 2007, Zhang, Bu, & Gao, 2013).
Research Question 2: Surgical Resection
This study tested the hypotheses associated with the following research question:
When comparing urban and rural patients with GBM, is there a significant difference in
the number of patients who experienced surgical resections?
H02: When comparing urban and rural patients with GBM, there is no significant
difference in the number of patients who experienced surgical resections.
H12: When comparing urban and rural patients with GBM, there is a significant
difference in the number of patients who experienced surgical resections.
Initially, a new measure was created which consisted of a dummy measure of
whether or not respondents had a surgical resection. In the overall sample of 33,202
patients, 24,493 (73.8%) had a surgical resection, while 8,709 did not (26.2%). A chisquare analysis was then conducted in order to determine whether a significant
association existed between these two measures. The chi-square analysis conducted in
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relation to this hypothesis failed to achieve statistical significance, χ2 (1) = .5707, p =
.450. Therefore, the null hypothesis was accepted; that is, there is no significant
difference in the number of GBM patients who experienced surgical resection. These
findings are new and add to the current body of knowledge. Research from the Glioma
Outcomes Project demonstrated that patient age, functional status, and complete resection
of the tumor were statistically significant prognostic indicators for patient survival (Laws
et al., 2003). However, complete surgical resection of the GBM tumor is impossible
because of the hyper-vascularity and invasiveness of the tumor. Therefore, near-total
resection is done to decrease the tumor size, relieve intracranial pressure, and improve
survival (Chandana et al., 2008).
Research Question 3: Treatment Options
This study tested the hypotheses associated with the following research question:
When comparing urban and rural patients with GBM, is there a significant difference in
the number of patients who experienced the adjuvant therapies of radiation treatment and
chemotherapy?
H03: When comparing urban and rural patients with GBM, there is no significant
difference in the number of patients who experienced the adjuvant therapies of radiation
treatment and chemotherapy.
H13: When comparing urban and rural patients with GBM, there is a
significant difference in the number of patients who experienced the adjuvant therapies of
radiation treatment and chemotherapy.

84
It should be noted that data for the SEER database are routinely collected on
cancer patients who undergo radiation treatments and chemotherapy administration.
SEER has a rigorous methodology for ensuring the quality and accuracy of collected
data. Over the last decade, SEER database administrators have ascertained that data
associated with chemotherapy administration are significantly under-reported. For this
reason, chemotherapy data were not included in the SEER database made available to the
public. Consequently, for this current study, the chemotherapy variable was not
measured.
Continuing with radiation treatments, for this research question, a new variable
was constructed that consisted of a dummy variable measuring whether patients received
radiation treatment. This measure was coded 1 for patients who received any kind of
radiation therapy including the categories of beam radiation, combination of beam with
implants or isotopes, radiation NOS method or source not specified, radioactive implants,
and radioisotopes, and was coded 0 in cases of no radiation, and missing if responses to
this question were refused. Out of this sample of 32,366 patients, it was found that
24,333 patients received radiation therapy (75.2%) while 8,033 (24.8%) patients did not
receive radiation therapy. As shown in Table 18, the use of radiation was slightly more
common among patients residing in urban regions compared to rural areas. The chisquare analysis conducted was found to achieve statistical significance, χ2 (1) = 18.3962,
p < .001. Therefore, the null hypothesis was rejected; that is, when comparing urban and
rural patients, there is a significant difference in the number of GBM patients who
experienced the adjuvant therapy of radiation treatments. In other words, more urban
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GBM patients undergo radiation therapy compared to their rural counterparts. These
findings are new and add to the current body of knowledge. Prior to 2005, the standard
of care for newly diagnosed GBM patients was surgical removal of the tumor (surgical
resection) followed by radiation therapy (adjuvant radiotherapy). The benefit of
chemotherapy had not been well established. However, in 2005, a landmark randomized
trial demonstrated the overall survival benefit of adding chemotherapy identified as
temozolomide with radiation following maximal surgical resection of the tumor (Stupp
et al., 2005). As a result of this landmark study, and given the dismal prognosis
associated with GBM diagnosis, multimodal aggressive therapy consisting of surgical
resection of the tumor, local radiotherapy, and systemic chemotherapy is done in an
attempt to prolong survival time.
Research Question 4: Survival
This study tested the hypotheses associated with the following research question:
When comparing urban and rural patients with GBM, is there a significant difference in
survival rates?
H04: When comparing urban and rural patients with GBM, there is no significant
difference with survival rates.
H14: When comparing urban and rural patients with GBM, there is a significant
difference in survival rates.
Of the overall sample of 33,176 patients, 4,056 (12.2%) rural patients survived
10.3 months while 29,120 (87.8%) urban patients survived 12.04 months. Survival data
are commonly depicted with a Kaplan-Meier curve (refer to Figure 10). To further
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explore this fourth research question, a Cox regression was conducted in which region
was used to predict survival time. This analysis again incorporated a total of 33,176
cases with the same number of failures and a total time at risk of 392,283 months. Urban
region was found to achieve statistical significance, with a hazard ratio of .882 (robust SE
= .015), p < .001, 95% CI = [.853, .913]. Additionally, this regression model was found
to achieve statistical significance, Wald χ2 (1) = 52.94, p < .001. Therefore, the null
hypothesis was rejected; that is, GBM patients who live in urban regions survive longer
than GBM patients in rural areas. This study is unique in that it is the first to demonstrate
a significant relationship between poorer survival for rural GBM patients compared to
their urban counterparts. However, the prognosis for patients diagnosed with GBM
remains poor despite ongoing therapeutic advancements (Stupp et al., 2005; Yuile et al.,
2006; Yabroff et al., 2012). Median survival from initial diagnosis is, at best,
approximately 1 year.
Research Question 5: Survival With Controlled Variables
This study tested the hypotheses associated with the following research question:
In the study population of GBM patients, is there a significant difference in survival rates
when controlling for region, race, age, sex, educational level, and median family income?
H05: In the study population of GBM patients, when controlling for region, race,
age, sex, educational level, and median family income, there is no significant difference
in survival rates.
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H15: In the study population of GBM patients, when controlling for region, race,
age, sex, educational level, and median family income, there is a significant difference in
survival rates.
In this analysis, the measures of region, race, age, gender, educational level, and
median family income were included as predictors of the number of survival months.
Since the data on the total number of survival months were found to be strongly
positively skewed and overly dispersed, a negative binomial regression was used for this
analysis. Skewness refers to the asymmetry of the data’s distribution. When data are
symmetrically distributed, data are not skewed, and the mean, median, and mode are the
same. Positively skewed data means that their distribution are asymmetric and the
“mean” of the data is pulled towards larger numbers. Since the data in this study are
described as strongly positively skewed, the mean is pulled in the direction of extreme
scores that are significantly large, and the mean is greater than the median and mode.
Overdispersion of data means there is greater variability in a data set than would
otherwise be expected; that is, the variance is larger than the mean.
When using negative binomial regression, dummy variables are created
(Gerstman, 2008, p. 337). For this study, the predictors noted above included a dummy
variable representing regional status, dummy variables representing Blacks as well as
individuals of other races and individuals whose race was unknown, a dummy variable
representing females, along with age, the percentage of individuals with less than a high
school education, the percentage with at least a bachelor’s degree as well as median
family income measured in $10,000s, which were all included as continuous measures.
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The results of the analysis found statistical significance with respect to the effects of
regional status, age, gender, and median family income. Significantly longer survival
time was associated with urban status, female patients, and higher median family income.
Additionally, greater age was associated with significantly reduced survival time. This
overall regression model was found to achieve statistical significance, with a pseudo R2 =
0 .0302. Therefore, the null hypothesis was rejected. Again, this study is unique in that it
is the first to show a statistically significant relationship between survival and GBM
patients living in urban versus rural regions, gender, family income, and age. There have
been studies that have examined significant prognostic factors for survival in primary
brain tumors. Results of these studies demonstrated that age is the single most significant
prognostic factor for survival in patients diagnosed with primary brain tumors, especially
when age is younger than 60 years (Chandana et al., 2008; Mineo et al., 2007).
Theoretical Framework of the Study
The theoretical framework used for this study is based on the behavioral model of
health services developed by Andersen (1995). This framework has been applied in
access to healthcare, determination of quality, and outcomes (Blustein & Weitzman,
1995; Fryer et al., 1999; Love & Lundquist, 1995; Phillips et al., 2000). Andersen’s
framework is based on the assertion that late access to cancer diagnostic services for
patients experiencing GBM may potentially lead to increased tumor size, decreased
treatment options, and decreased survival rates. Concerned with inequalities to medical
care access, Andersen initiated studies on the concepts of access in 1968. Andersen’s
model suggests that people’s use of healthcare relies on their general predisposition
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concerning health services, issues that enable or block utilization of services, and their
inherent need to seek health care. Andersen (1995) noted that the purpose of the initial
measures of access was to identify situations that either promote access to health care
services, or obstruct access to services. By 1995, Andersen revised the original focus on
access to a behavioral approach of health services use, recognizing that the use of health
services should maintain and/or improve the health status of the population, both
perceived by the population and/or evaluated by health professionals (Andersen,
Davidson, & Ganz, 1994).
Placing this study within the context of the theoretical foundation, study results
suggest the following: (1) Significant predisposing characteristics are age, gender, and
race; (2) Significant enabling resources are geographic regions of urban versus rural
locations, location and availability of healthcare resources, and income level; (3) The
individual need to access healthcare due to the sudden illness of GBM impacts the actual
use of health services. Given the preponderance of these factors suggest that delays in
accessing healthcare resources result in larger tumor size, fewer treatment options, and
poorer survival rates for rural GBM patients.
Limitations of the Study
First, this study explored a cohort of patients diagnosed with GBM obtained from
the SEER 18 database (National Cancer Institute, n.d.). Since this study focused only on
the subpopulation of adult patients diagnosed with GBM, there is an inherent sample
bias. Second, the potential presence of confounding conditions certainly posed a threat to
internal validity of the study. Internal validity is decreased if the observed effect is caused
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by uncontrolled conditions. Third, since GBMs are most common in the elderly who
have complex health issues, survival could be affected by potential confounding
conditions other than the GBM itself. Fourth, the SEER database reports only on cancer
information and incidence. It does not address lifestyle factors or causes of cancer. Fifth,
since the database covered a 23-year timeframe from 1988 to 2011, the migration of
patients lost to follow-up could result in an overestimate or underestimate of study
results. With the GBM population, survival is usually 12 to 15 months or less from time
of diagnosis. Since SEER does follow all patients until death, and the survival rate for
GBM patients is poor, the likelihood of losing patients to follow-up should be minimal.
Sixth, while there are numerous definitions of rural and urban areas, this particular study
was based exclusively on the SEER definitions of urban (metropolitan) and rural
(nonmetropolitan regions) which ultimately affect the generalizability of results. There is
no single, universally accepted definition of rural. However, counties are the most
commonly used geographic component of rural definitions. The advantages of using
“counties” to describe urban from rural areas are that they are simple to understand and
their boundaries are very stable over time. Additionally, many national health data sets
use counties as a core geographic unit. Finally, the SEER Extent of Disease was used to
characterize tumor size, and treatment options of surgery, radiation therapy, and
chemotherapy. These definitions need to be considered when comparing to other studies
that use other definitions of measurements. Additionally, SEER database administrators
ascertained that data associated with chemotherapy administration is significantly under-
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reported. For this reason, chemotherapy data was not included in the SEER database
made available to the public. Unfortunately, this variable could not be evaluated.
Recommendations
GBM is a lethal brain tumor with a terrible prognosis barely surviving a year
beyond the original diagnosis (Holland, 2000). While the results of this study provide
new information that certainly adds to the current body of knowledge, additional areas of
exploration are warranted. Since the SEER 18 database contain registry data representing
28% of the population in the United States, additional research should focus on other
areas of the U.S. to further explore the relationship of urban versus rural residence and
associated outcomes. Future studies could also focus on study outcomes categorized by
the different types of urban and rural regions utilized for this study. Additional studies
could also focus on survival of GBM patients and their proximity to cancer centers and/or
large, regional hospital. Finally, knowing the overall median survival of GBM patients of
12 to 15 months from diagnosis, perhaps future research should focus on long-term
survivors and the associated factors that differentiate them from the majority.
Implications for Social Change
GBMs are a major public health problem with more than 10,000 new cases
reported annually in the U.S. (Clarke, Butowski, & Chang, 2011; Wen & Kesari, 2008).
Despite recent advances in the standard of care, GBM prognosis remains grim.
Essentially, GBM is an incurable disease that ultimately leads to death within one year
from diagnosis. This study can significantly impact social change by identifying
geographical variables associated with health outcomes of GBM patients thereby leading
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to earlier detection and improved survival rates of individuals and populations. This
study also provides valuable information to lawmakers responsible for the creation of
healthcare policy and the allocation of healthcare resources.
Conclusion
GBM is a malignant brain neoplasm characterized by its destructive ability to
invade healthy brain tissue at an accelerated rate (Holland, 2000). Due to its lethality,
patients diagnosed with GBM have a dismal prognosis, barely surviving a year beyond
the original diagnosis. For this reason, Holland has referred to GBM as “the terminator”
(p. 6242). Since the vast majority of patients with GBM die of their disease within a
year, and very few have long-term survival, these particular tumors have drawn
significant attention in the research world. There is a plethora of research seeking to
identify risk factors, genetic connections, immunological explanations, viral vectors, and
novel therapeutic approaches focused on tricking the GBM tumor into submission and
thereby improving survival.
This quantitative, retrospective study collected data on all adult GBM patients
diagnosed from 1988 to 2011, and the ultimate purpose was to determine if differences in
tumor size, treatment options, and survival rate occurred in urban and rural GBM patients
in the United States. Results showed statistically significant differences in tumor size at
diagnosis and radiation treatments in rural patients compared to urban patients, and rural
GBM patients had poorer survival rates than urban GBM patients. Finally, when
controlling for region, race, age, gender, educational level, and median family income,
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significantly longer survival time was associated with urban status, female patients,
younger patients, and higher median family income.
Every research attempt in the GBM field should be with guarded optimism in that
we get one step closer to successfully treating this devastating disease. For those patients
and families who have faced this terminal condition, the hope is to live long enough until
a cure is available. Until that time comes, the research imperative in the GBM arena
takes on a sense of urgency.
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